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Abstract 
 
 
 
 
 
Chronic  Myeloid  Leukaemia  (CML)  is  a  myeloproliferative  disorder  whose  
hallmark  is represented  by   the  BCR-ABL1  fusion  gene.  The  mechanisms  
associated  with  disease progression and development of resistance to treatment are 
still little understood and so far the best characterised mechanism of resistance is  the  
expansion of a CML clone bearing an amino-acid  substitution  in  the  BCR-ABL1  
kinase  domain   (KD).  Screening  by  direct sequencing a large cohort of patients 
of over 260 CML individuals at various  stages of disease, I assessed the incidence 
of BCR-ABL1 KD mutations and found that, in accordance with  previous works, the 
detection of mutations was strongly linked to clinical resistance. Furthermore, 
patients with amino acid substitutions within the P-loop region had commonly 
presented with features of advanced stages at some point during disease course, 
accounting for the vast majority of all resistance-associated  mutations. To evaluate 
the impact of the diverse BCR-ABL1 mutations on individual prognosis I stratified the 
whole cohort of patients on the grounds of disease phase at time of mutation 
detection and found that  events of progression from chronic to advanced phase were 
mostly represented by patients harbouring KD   mutations  within  the  P-loop  and  
gatekeeper  domains.  Detection  of  BCR-ABL1 mutations, however, does not 
always explain resistance to tyrosine-kinase inhibitors (TKIs). With several studies 
having indicated  a role of certain Src family kinases (SFKs) in the disease 
progression, we have hypothesised that the ineffectiveness of treatment might be due 
to the introduction of point mutations within the TK domain of one or other of the three 
SFKs being implicated in the development and progression of CML, namely Hck, 
Lyn, and  Fyn. Systematic  evaluation  of  the  mutations  arising  after  treatment  with  
2G-TKIs  has  been performed  over a subgroup of the initial cohort of CML 
patients, constituted by 24 non- responder CML patients  described as negative for 
BCR-ABL1 mutations. Screening these patients for SFK Hck, Lyn and Fyn KD 
mutations, however, could not reveal the presence of any abnormality, suggesting that 
the clinical heterogeneity of CML requires therefore further investigation of  
alternative  mechanisms  responsible  of  the  multifactorial  resistance  and relapse of 
CML patients. 
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I. Background 
 
 
 
 
Chronic myeloid leukaemia (CML) is one of the most extensively studied human 
malignancies. CML is a myeloproliferative disorder characterised by the malignant 
expansion of hemopoietic  stem cells (HSC) in the bone marrow. Underlying the 
aetiology of this disease is a balanced reciprocal chromosomal translocation between 
the long arms of chromosome 9 and 22, t(9;22)(q34;q11), generating the Philadelphia 
(Ph+) chromosome
1
, named after the city where it was first discovered, and whose 
presence usually confirms the diagnosis of CML, occurring in 95% of the patients with 
CML. This chromosomal aberration leads to  the  formation  of  the  chimeric  BCR-
ABL1  oncogene,  characterised  by  the juxtaposition of parts of two genes: the 
ABL1 (human homologue of the Abelson murine  virus)  proto-oncogene,  present  on  
chromosome  9,  and  BCR  (breakpoint cluster region) gene, on chromosome 22. As a 
result, a 5’ end of BCR and a 3’ end of ABL1  are  fused  together  on  a  shortened  
chromosome  22.  The  leukaemogenic potential of the BCR-ABL1 fusion gene 
resides in the  constitutively activated tyrosine kinase  of  its  ABL1  portion.
2    
The  
normal  ABL1  protein  has  a  physiologically controlled  kinase  activity  and  is  
found  in  both  the  nucleus  and  the  cytoplasm, shuttling between these two 
domains under the influence of nuclear localisation export signals whereas BCR-
ABL1 is essentially cytoplasmic.
3  
Nuclear ABL1 has predominantly pro-apoptotic 
functions, playing an essential role in the cellular response to genotoxic  stress; in  
contrast, BCR-ABL1 is  mainly anti-apoptotic and despite maintaining the ABL1-
derived nuclear  export and nuclear localisation domains, it seems unable to penetrate 
the nucleus.
3  
The main reason why the BCR-ABL1 protein is trapped in the cytoplasm 
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is its aberrantly active tyrosine kinase.  Furthermore, the hybrid BCR-ABL1 oncogene 
leads to the transformation of a HSC to a leukaemic stem cell (LSC). Proof that a 
CML LSC derives from transformation of a HSC is provided by the observation that 
BCR-ABL1 is found in all myeloid lineages, and some lymphoid cells, including a 
small fraction of T and NK cells
4
, but clinically it only affects granulocytes. BCR-
ABL fusion protein occurs in the majority of patients with CML and in about 15-25% 
of the adults with acute lymphoblastic leukaemia (ALL).
5
 CML is a triphasic disease: 
more than 90% of patients are diagnosed in an indolent chronic phase (CP), where 
mature granulocytes are still produced,  but  there  is  an  increased  number  of  
myeloid  progenitor  cells  in  the peripheral blood. The natural history of CML is 
progression from CP to an intermediate accelerated phase  (AP)  characterised  by  
15%–29%  blasts  in  blood  or  bone  marrow,  >20% basophils in blood, 
thrombocytosis or thrombocytopenia  unrelated to therapy, or clonal cytogenetic 
evolution. AP within a year transforms into a terminal  blastic phase/blast crisis 
(BP/BC), where haemopoietic differentiation has become arrested and  immature blasts 
accumulate in the bone marrow and spill into the circulation, with over >30%  blasts  
in  bone  marrow  and  >50%  in peripheral   blood. BP is characterized by extra-
medullary blastic   infiltration, defined as leukemic infiltration in organs other than liver, 
spleen, and lymph nodes and that   is   represented   by   a   population   of   myeloid   or   
lymphoid differentiation-arrested progenitor cells. These cells show enhanced 
proliferation and survival  associated  with  resistance to  chemotherapy and  poor  
prognosis.
6   
Before the advent of tyrosine kinase inhibitors the entire continuum from CP to 
BP lasted on average 3 to 5 years, but the range was wide. Patients may present in any of 
these three phases and some of them progress directly to BP without an intermediate AP.  The 
chapters below describe more in depth the triphasic nature of CML and the clinical 
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features of its phases. 
 
 
 
 
 
 
 
 
 
 
I.I Pathogenesis of Chronic Myeloid Leukaemia 
 
 
 
 
 
I.I.A. The BCR-ABL1 Fusion Gene 
 
Several  experimental  models have established a causal  relationship between BCR-
ABL1 and CML.
   
BCR-ABL1-expressing  CD34 +  cells  in culture demonstrated 
several features characteristic of primary CML progenitors including increased 
proliferation in committed and primitive progenitor culture, reduced adhesion to 
fibronectin, and reduced chemotaxis to stroma-derived factor-1.
7
 Retrovirally   
transduced   BCR-ABL1- positive   murine cells generated  mice that developed several 
hematologic malignancies: prominent among them was a myeloproliferative syndrome 
closely resembling the chronic phase of human CML.
8
 Inactivation of ABL1  kinase  
activity  by  substituting  a  lysine  with  arginine  at  residue  1176 (K1176R) in the 
ATP-binding pocket, confers a non-leukaemic status to BCR-ABL1- expressing mice, 
even when the mutant is expressed in  hemopoietic stem cells (HSCs).
9 
The breakpoints  within  the  ABL  gene  take  place  either  upstream  of  exon  1b, 
downstream of  exon 1a, or, more frequently, between exons 1b and 1a (fig1.1).
10
 
Variable  breakpoints  take  place  also  within  the  BCR  gene,  all  occurring  within 
introns, leading  to the formation of different BCR-ABL1 fusion gene variants. In 
most patients with CML and in  one-third of those with Ph-positive B-cell acute 
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lymphoblastic leukaemia (Ph+ B-ALL), the  breakpoints within BCR map to a 5.8- 
kilobase (kb) area spanning exons e13-e14 (formerly called b2-b3) or can affect the 
intron downstream of exon 19.
11  
The former is referred to as the major breakpoint 
cluster region (M-BCR). In CML patients, alternative splicing gives rise to different 
fusion  transcripts, which encode for distinct proteins: p190
BCR-ABL1  
(Mr   190,000) 
(less than 5% of cases), p210
BCR-ABL1 
(Mr  210,000) (in 95% of cases), and p230
BCR- 
ABL1 
(Mr  230,000) (in  granulocytic leukaemia, less than 1%). In about 95% of the 
CML patients the BCR-ABL1 fusion transcripts e14a2 (former b3a2) and e13a2 
(former b2a2)  can be detected (reviewed in Barnes et al., 2002). The translated 
product is in each case a p210 kD BCR-ABL1 protein.
12 
In patients with Ph
+  
ALL a 
shorter  transcript  version,  called  BCR-ABL-e1a2,  predominates,  leading  to  the 
production of a p190
BCR-ABL 
protein. 
Both BCR-ABL1 proteins p190 BCR-ABL1 and p210 BCR-ABL1 are characterized 
by a dramatically increased tyrosine-kinase activity, as compared to that of normal 
ABL protein, leading to aberrant phosphorylation of downstream target molecules. 
This abnormal BCR-ABL1 kinase activity is assumed to be sufficient and necessary to  
initiate  CML,  leading  to  stimulation  of  mitosis,  increased  genetic  instability, 
decreased stromal regulation and finally inhibition of apoptosis.
13
 
 
 
 
 
 
 17 
 
 
 
 
 
 
Fig1.1. Schematic representation of the ABL1 and BCR genes and the BCR-ABL1 kinase (from 
Quintas-Cardama, Blood 2009). (A) BCR contains 23 exons. The 3 breakpoint cluster regions (m- BCR, 
M-BCR and µ-BCR) are represented. ABL1 contains 2 alternative first exons (1b and 1a) and the arrows 
represent the three different breakpoints in ABL1. The combination of different breakpoints in the 2 genes 
creates different fusion transcripts with distinct molecular weight (P190, P210, P230). (B) Structural 
modularity of ABL1b and BCR-ABL1 kinases. ABL1 kinase is constituted by a central core composed of 
a tyrosine kinase domain,  SH2  and SH3 domains and, at the NH2-terminus a “cap” region. Two isoforms 
of ABL1 (human types 1a and 1b) are generated by alternative splicing of the first ABL1 exon. ABL1b 
contains a myristate site (Myr-NH) at the extreme end of the NH2 terminal, which binds to the KD and 
keeps the SH2-SH3 autoinhibitory structure in place (i.e. in the “off state”). 
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I.I.B. Anatomy and autoregulation of the BCR-ABL protein 
 
 
 
 
BCR-ABL1 kinase contains a series of functionally distinct domains (Fig.1.1). The 
NH2-terminus  of BCR-ABL1 includes the “Cap” region, which is present in two 
different isoforms created by alternative splicing of the first exon, named 1a and 1b. 
ABL1b, differently from ABL1a, is expressed at higher levels and myristoylated at its 
extreme end of the amino-terminal region. In addition, ABL1 contains a tyrosine kinase 
domain, preceded by highly conserved Src homology motifs 2 and 3 (SH2 and SH3),
14  
a 
DNA-binding domain, an actin-domain, as well as 3 nuclear localisation signals and 1 
nuclear export signal which determines ABL1 subcellular localisation in response to 
environmental stimuli. 
 
 
 
 
 
I.I.C. Signalling pathways downstream of BCR-ABL1 kinase 
 
 
 
BCR-ABL1  induces  activation  of  numerous  downstream  signalling  pathways 
activated  by   BCR-ABL1,  all  contributing  to  the  oncogenic  transformation  of 
leukocytes in CML.
15  
Phosphorylation of BCR Tyr 177 serves as a docking site for the 
SH2 domain of GRB2, which binds  GRB2 and SOS, recruiting in turn RAS and 
GAB2. Because the former is essential for the  mitogenic RAS-MAPK pathway 
activation,  this  results  in  transcription  of  BCL-2  gene.
16   
In  turns,  GAB2  causes 
constitutive activation of the PI3K, which through a signalling pathway  increased 
transcription of MYC gene and stabilizes MYC protein. BCR-ABL also activates the 
SRC  family  kinases  HCK  and  LYN  that  recruit  STAT5,  which  modulates  the 
antiapoptotic BCL-X gene transcription.
17  
Therefore, the net effect of BCR-ABL1 
kinase activation is the promotion of both cell proliferation and survival. 
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I.I.D. Epidemiology 
 
 
 
 
Chronic  myeloid  leukaemia  represents  approximately 15%  of  all  types  of  adult 
leukaemias,  although  the ratio  is  higher in  East  Asia and  Japan,  where chronic 
lymphocytic leukaemia is  more infrequent. Its incidence is of about 2 cases every 
100,000 people per year, with a median age at presentation of 45 to 55 years. From 12 to 
30% of patients are 60 years of age or older. Although the mechanisms of disease 
progression remain largely unknown, the risk of developing CML is higher following 
exposure to radiation. This is evident from studies of survivors of the atom bomb 
explosions in Japan in 1945 and from the follow-up of patients treated with radiation for 
ankylosing spondylitis and cervical cancer. 
There is no known association of CML with any infectious agent or chemical exposures. 
No familial predisposition has been implicated in CML but there are isolated reports of 
CML occurring in first degree relatives of affected individuals. Relapse of CML 
originating in donor cells following a related donor allogeneic stem cell transplant (SCT) 
has been recorded. 
 
 
 
I.I.E. Clinical manifestations 
 
 
 
Chronic myeloid leukaemia if left untreated leads to death within a few years. The 
most consistent  clinical laboratory manifestation is hyperleukocytosis. CML is a 
triphasic disease. Patients are typically in the chronic phase when CML is diagnosed, 
whose duration is variable and depends time of diagnosis as well as the therapies useds.  
Invariably the disease progresses eventually to a more advanced phase which is usually 
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sub-classified as either accelerated phase – an intermediate phase, characterised by a 
more insidious transformation that can last for  month or years - or blastic 
transformation, with the latter being especially resistant to therapy, resembling an acute 
leukaemia and leading to death within 6 to 8 months. 
Chronic phase 
90% of CML patients present in chronic phase and in recent years up to 50% of them 
have  been   diagnosed  before  the  onset  of  symptoms  thanks  to  the  increasing 
awareness  of  today’s  population  undergoing  routine  medical  check-ups.  When 
present, symptoms may include fatigue, increased sweating, fever, or bone pain. 50-
70% of individuals at CML diagnosis show splenomegaly.  The spleen extends 
considerably in  length,  resulting in the occupation of all  the left  side of the abdomen  
and occasionally becoming palpable in the right iliac fossa. 
Accelerated and blastic phases 
 
In  contrast  to  the patients  in  chronic phase,  patients  in  advanced  phases  nearly 
always will present some of or all the features described above, with fever and bone 
pain being the most frequent. In addition there may be episodes of infection and the 
liver and spleen are usually highly enlarged in size. 
 
 
 
 
 
 I.I. F. Diagnosis 
 
The diagnosis of CML is generally straightforward and is obtained from the typical 
appearances  of  the  peripheral  blood  and  bone  marrow.  The  most  obvious  and 
common  features  of  chronic  myeloid  leukaemia  are  neutrophil  leukocytosis  
basophilia. The detection of the Ph+ chromosome through cytogenetic analysis is 
confirmatory.  About  5%  of  patients  do  not  present  the  Ph+  chromosome  and 
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confirmation of diagnosis is dependent on finding the BCR-ABL1 rearrangements by 
either reverse transcription polymerase  chain reaction (RT-PCR) or fluorescent-in- situ-
hybridisation   assays.   In   a   lower   minority   of   cases,   however,   no   Ph+ 
chromosome or BCR-ABL1 transcripts can be detected, and they are  referred to as 
Philadelphia negative (Ph-) and BCR-ABL negative, or also atypical CML, and they are 
considered as a separate disease entity.  
Quantitative real-time PCR (qRT- PCR) thanks to  its high sensitivity represents a 
suitable assay to monitor residual disease  after  cytogenetic  remission.  Considerable  
efforts  have  been  pursued  to standardise PCR techniques by definition  of an internal 
standard to quantify BCR- ABL1  levels  and  of  an  international  set of 
recommendations  from  the  European  LeukemiaNet (table 1A).
 18
 
 
 
 
Table 1A. Current recommendations for monitoring chronic-phase CML during imatinib therapy, 
modified according to the recommendations from the European LeukemiaNet. 
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I.I.G. Prognostic factors for non-transplant therapy 
 
 
 
 
The disease phase is the strongest prognostic factor in chronic myeloid leukaemia, 
with diagnosis in accelerated or blast crisis phases showing a dramatically worse 
outlook. In regard to CML in chronic phase, various scoring systems have been 
devised in order to predict the prognosis of individual patients. The most widely used is 
the final model arising from the Sokal score (developed in 1984), whose data were 
analysed from 813 patients, most of which received busulphan.  According to four 
weighted  clinical  and  laboratory  values  (age,  spleen  size,   platelet   count,  and 
peripheral  blood  blasts  cell  percentage),  patients  can  be  classified  into   three 
prognostic groups for a 4-year survival; with a survival probability up to 62%, 43% 
and 33%, patients were segregated respectively into low-risk, intermediate-risk and 
high-risk groups. The Sokal score in an individual patient is no more than the relative 
risk (RR) for survival and it is based on the Cox proportional hazards equation using 
four patient variables (namely platelet  count, age, blast count and spleen size). This 
model has been recently revised with a new  prognostic classification, the Hasford 
score, which derived from the study of over 900 CML patients on interferon (IFN) and 
calculated using  the  classic  four  Sokal  variables  together  with  two  others,  
namely  blood percentage of eosinophils and basophils (Table 1B). In the new 
scoring system, patients were classified into the low-, intermediate- and high-risk 
groups according to a 5-year survival probability of 76%, 55% and 25% respectively.  
More recently, a new scoring system (European Treatment and Outcome Study 
[EUTOS] score) was developed by the European Leukemia-Net using data from 2,060 
patients who were treated with imatinib-based regimens. The EUTOS score is similar to 
 23 
 
the Sokal score, and patients are classified into two different prognostic groups (i.e. high 
and low risk) on the basis of the percentage of basophils in the peripheral blood and the 
spleen size at diagnosis.
19
 It has been suggested that the EUTOS score has superior 
prognostic power when compared with the Sokal and Hasford scores.
19 
However, a 
Swedish study reported that the Sokal but not the EUTOS score predicted relative 
survival in CML patients.
20 
 
Ideally, a prognostic classification score should be able to identify patients with poor 
risk independently of whether patients are treated in the community or part of clinical 
trials. The Sokal score has been used for nearly 30 years and has been validated 
extensively in different clinical settings and therapies; clinicians need to be cautious 
before adopting a new prognostic system that has not yet been validated in a truly 
independent manner.
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Table 1B. Main prognostic risk scores in chronic phase CML 
Age is expressed in years, spleen in cm below costal margin, platelets in 10
9
/1itre, and blasts (peripheral 
blood) as a percentage. The relative risk (RR) according to Sokal is based on patients treated 
with conventional chemotherapy and it is expressed as exponential of the total. The RR according to 
Hasford is defined based on patients treated with INF-based regimes and it is calculated as total x 1000. 
 
 
 
                                                                   Calculation by Sokal et al Calculation by Hasford et al 
Age                                                     0.116 x (age – 43.4)                                                  0.666 when age ≥ 50 yrs                                                                         
Spleen                                                     0.0345 x (spleen – 7.51)           0.042 x spleen 
Platelet count, x 109/L 0.188 x [(platelet count / 700)2  – 0.563] 1.0956 when platelet count ≥ 1500 x 109/L 
Blood myeloblasts, % 0.0887 x (myeloblasts – 2.10) 0.20399 when basophils >3% 
Blood basophils, % NA 0.0413 x eosinophils >3% 
Blood eosinophils, % NA 
Relative risk (RR) 
Low                                                                      <0.8 ≤ 780 
Intermediate 0.8 – 1.2 781 – 1480 
High                                                                       >1.2 >1480 
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I.I.H. Disease progression and transformation 
 
 
 
 
The mechanisms  of  progression  and  transformation  in  CML  to  blast  phase  are 
complex and not entirely understood, partially still due to the lack of adequate animal 
models of BCR-ABL-induced leukaemia with a long, human-resembling chronic phase, 
necessary for right evaluation of the mechanisms involved in disease evolution. Numerous 
factors have been implicated as critical in the transformation from chronic to blastic phase 
CML. 
A) BCR-ABL1 expression: the constitutive expression of the BCR-ABL1 fusion gene 
is  paramount in almost certainly causing CML and for its evolution. In fact, BCR-ABL1 
expression is considerably higher in BP than in CP.
21
 Although the reason for the 
increment of BCR-ABL1 transcript levels is not well understood, this phenomenon may 
result from selective pressure favouring the expansion of highly proliferative/poorly 
differentiated leukaemic clones. 
B) Differentiation arrest: it has been demonstrated that BCR-ABL1 suppresses the 
expression of  CEPBα, member of the  basic leucine zipper family of transcription 
factors that is essential for normal granulocytes differentiation. Although CEPBα is 
normally expressed in CML-CP samples, its expression is undetectable in CML BP 
cells,
22 
suggesting that a lack of CEPBα activity reflects the emergence of a more 
primitive population. 
C) Genomic  instability:  still  to  be  resolved  is  the  dilemma  of  whether  the 
accumulation of additional chromosomal abnormalities in CML is driven by BCR- 
ABL1 and/or by pre-existing mechanisms responsible for the t(9;22) itself. However, 
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what we know so far is that the mechanisms of genome surveillance and DNA 
repair are  impaired  in  CML,  which  could  explain  the  occurrence  of  the  
chromosomal aberrations that characterise the  blastic transformation process. At 
the heart of the genome surveillance system are the ataxia telangiectasia mutated 
(ATM) and ataxia telangiectasia  and  RAD3-related  (ATR)  nuclear  protein  
kinases  that  function  as DNA damage “sensors”. In CML only ATR has been 
documented to be inhibited.
23
  
Following exposure to cytogenetic agents, such as etoposide, BCR-ABL1 from its 
cytoplasmic  localisation  has  been  shown  to  translocate  to  the  nucleus  and  
bind ATR.
23 
ATR is inhibited leading to a reduced activation of its substrate, 
checkpoint kinase 1 (CHK1), hence the abrogation of the intra-S-phase cell cycle 
checkpoint.
24
  
Moreover,  it  has  been  demonstrated  that  the  BCR-ABL1  induces  
endogenous reactive oxygen species (ROS), which results in chronic oxidative 
damage, double- strand breaks (DSBs)  and mutagenesis. The repair of DNA DSBs 
is taken over in mammalian  cells  by two  mechanisms:  non-homologous  end-
joining  (NHEJ) and homologous recombination (HR). Both of these pathways 
have been indicated to be faulty   in   CML,
25    
suggesting   that   BCR-ABL1-
mediated   ROS   generation   in combination with aberrant genome repair leads to 
a mutator phenotype in CML cells and results in genomic instability.
26 
However, 
we cannot exclude the possibility that pre-existing conditions, which lead to 
t(9;22), may work in concert with BCR-ABL to accumulate chromosomal errors. 
D) Telomere shortening:  typical of many other solid tumours and leukaemias, 
in CML the rate  of telomere loss increases with disease progression from CP to 
BP. The degree and rate of shortening has also been found to be prognostic for the 
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length of time to disease evolution. 
27 
It just remains an open question whether 
telomere shortening is a cause of disease evolution in cancer (for an as yet 
unknown mechanism), or whether it is merely a symptom caused by the turnover of 
malignant cells.
28
 
E) Loss  of  tumour  suppressor  function:  TP53 plays a major role in chronic 
myeloid leukaemia. In particular, isochromosome 17, resulting from the loss of 
chromosome 17 short arm where TP53 maps, is one of the most frequent alterations 
detected during disease progression from chronic phase to the blast crisis.
29,30
 
Another tumour suppressor  gene that is  associated  with  CML progression  is  the 
serine/threonine phosphatase 2A (PP2A), a major cellular serine/threonine 
phosphatase working to down-regulate activation of mitogen-activated protein 
kinase cascade and the PI3K pathway. The activity of this gene in BP is 
negligible, while  only moderately impaired in CML CP CD34+ cells. BCR-ABL1 
kinase inhibits PP2A by up-regulation of SET (I2PP2A), a nucleus/cytoplasm-
localised phosphoprotein that inhibits PP2A, activity that is mediated via the 
heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1). SET expression has 
been found to be markedly high in solid tumours and leukaemias.
31 
It is possible 
that the expression of active PP2A is incompatible with disease progression in CML, 
as this phosphatase recruits and activates the Src homology region 2 domain 
containing protein tyrosine phosphatase 1 (SHP1), which catalyses the 
dephosphorylation of BCR-ABL1. This, in turn, promotes the downregulation of the 
latter through proteasomal degradation. 
31
 
Although not a  universal  requirement  for   disease progression,  abnormalities  of 
other  tumour-suppressor  genes are associated with blastic transformation in 
subgroups of patients with CML. 
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I.II. Management of Chronic Myeloid Leukaemia 
 
 
I.II.A Assessment of response to therapy 
 
 
 
As for any disease, the ultimate measure of the efficacy for each therapy is 
judged by its individual impact on overall survival (OS) and event-free survival 
(EFS). Nevertheless, for a tumour with a relatively long disease course such as 
CML, an earlier assessment of efficacy is generally evaluated through the use of 
surrogate markers.  Without r ece iv in g  any treatment, a  CML  patient  generally 
survives between approximately 3 to 5 years. It is possible to define three levels 
of disease control in CML. Complete haematological response (CHR) defines the 
normalisation in count and differential  of  the  white  cells,  together  with  the  
disappearance  of  all  disease symptoms and the resolution of prior splenomegaly. 
Complete cytogenetic response  (CCyR)  classifies  the  absence  of  Ph+ 
metaphases by using classical cytogenetics, with at least 20 metaphases available 
for analysis, whereas major cytogenetic response (MCR) specifies the presence of 
less than 35% Ph+ metaphases. Partial cytogenetic response (partial CyR) i s  
defined as the absence of detectable BCR-ABL1 mRNA in real-time reverse 
transcriptase quantitative PCR (RT-PCR) and is not equivalent to eradication of 
leukemia since there may be minimal residual disease (MRD) below the lower limit 
of detection of the test.
32
 The paramount treatment goals for CML include the 
eradication of the leukaemic clone from the bone marrow, or prolongation of CP 
with sustained remission and minimal drug toxicity. To date, however, the only 
proven therapy resulting in a complete eradication of the malignant clone from 
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the bone marrow is allogenic stem cell transplantation, while first- or second- 
generation tyrosine kinase inhibitors obtain primarily results in the control of the 
CP and in only 5% of patients we have evidence of eradication of the disease by 
the most sensitive technique used to date, molecular monitoring. 
 
 
 
 
 
 
 
 
 
 
 
 
I.II.B CML treatment before imatinib 
 
 
 
 
The first  arguably  effective  treatment  of  CML  is  represented  by  
radiotherapy, introduced in  clinical practice at the beginning of 1900s and 
remaining standard therapy for over five decades. By the 1960s, radiotherapy was 
replaced by oral alkylating  agents,  whose rapid  development  led  to  the 
introduction  of busulphan followed by interferon, which  together  with  the 
introduction of cytarabine  in the late 1990s was  part  of  the  conventional 
cytoreductive  therapy, with which it became possible to produce sustained 
cytogenetic responses in up to one-third of patients. 
33
 
Although one randomised study indicated that the combination of interferon and 
 
cytarabine is more effective than interferon alone, 
34  
it was not confirmed by a 
subsequent clinical trial, which showed no improvement in overall survival.
35 
Using RT-PCR,  BCR-ABL1  mRNA  is  still  detectable  in  patients  treated  with  
INF, indicating that these long-term remissions amount only to a clinical cure,  
resulting in durable hematologic and cytogenetic remissions, rather than a 
biological cure of the disease (resulting in molecular evidence absent of very limited 
residual disease).  
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Hematopoietic stem cell transplant (HSCT), is so far the only treatment capable 
of disease  eradication,  with  the  majority  of  patients  achieving  RT-PCR  
negativity. Long-term  disease  free  survival  is  in  a  range  of  50  to  80%  in  
most  studies.
36
 However,  allografting  has  its  limitations,  due  to  significant  
transplant-related morbidity and mortality. 
 
 
 
 
 
 
 
 
I.II.C ATP-competitive BCR-ABL1 inhibitors 
 
 
 
 
Current established first-line therapy for all phases of CML is imatinib mesylate 
(Glivec/Gleevec/IM/STI-571; Novartis), a 2-aminophenylpyrimidine compound 
that can specifically target and inhibit the kinase activity of both normal ABL1 and 
oncogenic BCR-ABL1. IM is able to inhibit ABL1, platelet derived growth factor 
receptor α and β (PDGFRα , PDGFRβ), and Kit. Therefore, IM may be effective in 
targeting all the fusion proteins containing these activated kinases,  including 
BCR-ABL1, Ph+ ALL,  FIP1L1-PDGFR,  and  ETV6-PDGFR  respectively  in  
CML,  eosinophilic leukaemia,  chronic  myelomonocytic  leukaemia  and  some  
infrequent  forms  of CML.
37   
In regard to the mechanism of action,  IM binds 
to the inactive, closed conformation of ABL1 kinase domain. IM is wedged 
between the N-lobe and C-lobe of the ABL1 kinase. Part of the IM molecule 
occludes the ATP binding site with the remaining part further  penetrating into the 
hydrophobic region of the kinase and jamming itself between the activation  loop 
and helix-αC (fig. 1.2).  ATP is thus prevented from reaching its binding site, 
holding the kinase in  an  inactive status. The link between IM and BCR-ABL1 is 
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stabilised by the formation of six  hydrogen bonds involving the aminoacid (AA) 
residues Met318, Thr-315, Glu-285, Asp-381, Ile-360 and His-361. The bond is 
further stabilised by the formation of a number of van der Waals   interactions,  
through  the  AA  residues  Ile-293.  A  hydrophobic  cage  is completed with AA  
residues  Leu-370,  Leu-298,  Leu-354, Val-379, and Phe-382 around the phenyl 
ring adjacent to the piperazinyl-methyl group of imatinib.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2: Binding of Imatinib to the tyrosine kinase Abl (from 
http://www.cellbiol.net/ste/rpimages.php). Only the catalytic domain of the tyrosine protein kinase 
Abl is shown. Imatinib binds the ATP binding pocket of the kinase in its inactive conformation. The 
activation segment is not phosphorylated and covers the substrate binding site. In fact, imatinib 
prevents outward movement of the activation segment. 
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Thanks to its remarkable efficacy, since its introduction it has revolutionised the 
management  of   CML,  regardless  of  disease  phase. Recent studies have 
identified the presence of small numbers of primitive  “quiescent” cells that are 
refractory to the pro-apoptotic effect of both Glivec  and  conventional  
chemotherapy  agents.  The  insensitivity  of  these  non- dividing stem cells has 
also important implications on CML management regarding the relapse following 
imatinib-induced response.
38
 
Nilotinib (AMN107/Tasigna; Novartis) is a phenylamino-pyrimidine derivative that 
is structurally related to imatinib. Nilotinib is 10-30 fold more potent than imatinib 
in inhibiting activity of the Bcr-Abl tyrosine kinase and proliferation of Bcr-Abl 
expressing cells. The drug effectively inhibits the auto phosphorylation of Bcr-Abl 
on Tyr-177 that is involved in CML pathogenesis. Synergistic activity of imatinib 
and nilotinib has been reported following coadministration. This might be a result of 
the fact that the drugs are taken up in cells by different mechanisms: imatinib influx 
is dependent on OCT1 but nilotinib is not. Nilotinib is also not a substrate for the 
efflux transporter P-glycoprotein pump, unlike imatinib.  Resistance to nilotinib is 
associated with a limited spectrum of Bcr-Abl kinase mutations that mostly affect 
the P-loop and T315I.
39
 
Dasatinib (BMS-354825, Sprycel; Bristol-Myers  Squibb) is a potent, oral 
inhibitor of BCR-ABL1, which in addition to bosutinib binds to SRC-family 
kinases (SFKs),   which   may   contribute   to   CML   disease   progression   and   
treatment resistance.
40 
Dasatinib is 300 times more potent than imatinib and is 
effective against the imatinib-resistant active conformation of the kinase domain. 
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Haematological and cytogenetic  responses  are  long-term  in  patients  with  
chronic  phase  disease,  but response  durability  decreases  in  the  advanced  
phases.
41,42,43    
Despite  causing  a significant reduction in the total number of 
CD34
+
CD38
-
CML blasts  compared  to imatinib, dasatinib still fails to eliminate 
the primitive quiescent SC population.
44
 Bosutinib (SKI-606; Wyeth) is another 
dual Src-family kinase/abl inhibitor, with a potent  antiproliferative effect against 
imatinib-sensitive and-resistant BCR-ABL1
+ 
neoplastic cells and effective against 
both inactive and intermediate conformations of BCR-ABL1.
45    
SKI-606  is   
effective  in  suppressing  the  proliferation  of  CML progenitors,  but  is  
moderately  capable  in  inducing  apoptosis  of  the  primitive, quiescent fraction. 
Furthermore, unlike dasatinib and  nilotinib, bosutinib does not have effect on Kit 
and PDGFR and has more favourable toxicity profile.
46
 Several other compounds 
have been developed, but will not be described here as they are not yet in routine 
clinical practice. 
 
 
 
 
 I.III Mechanisms of resistance to TK inhibitors in CML 
 
 
 
Several studies have showed that a long-term favourable outcome of CML is more 
likely to be achieved when IM is given in newly diagnosed  patients in chronic-
phase disease. Patients passed to IM as second-line therapy  after  IFN  failure,   
showed  less  convincing  sustained  remission  rates. Nonetheless,  even  a  
consistent  number  of  newly  diagnosed  patients  experience treatment failure. Out 
of the patients included in the International Randomised Study on  IFN  and  IM  
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(IRIS),  circa  25%  failed  because  of   refractoriness  (primary resistance), or loss 
of response after attainment of initial response and progression of the leukaemic 
clone (secondary resistance), or intolerance. In 2009 expert panels of the European  
LeukemiaNet  updated the definition of  treatment  failure  as  based  on  
haematological, cytogenetic and molecular responses, taking into consideration the 
time on therapy.
18
 The initial goal is represented  by the normalisation of 
peripheral blood ( P B)  counts in association with less than 5% of blasts in PB, 
ideally after three months or less of treatment, named complete haematological 
response (CHR), which is the earliest monitoring point. Response to treatment is 
then monitored by bone marrow metaphase chromosome analysis (using at least 20 
metaphases), which determines a cytogenetic response, whose level is based on the 
number of   Ph+ metaphases.  Absence of Ph+ metaphases defines a complete 
cytogenetic response (CCyR), which should be attained by 12 months. After CCyR 
achievement, further monitoring of BCR-ABL1 is then done by either by 
fluorescence-in-situ hybridisation, with a  sensitivity of up to 10
-3
 or, preferably, 
by a quantitative real-time PCR assay, with a detection sensitivity of 10
-5
.
18
 
Finally, patients should achieve a three- or more log reduction in the concentration 
of BCR-ABL1 transcripts compared to a standardised baseline (being by definition 
a value representing the initial level of a measurable quantity, e.g BCR-ABL1 
transcript initial level), which is now become synonymous with major molecular 
response (MMR). MMR is generally regarded as a prognostically favourable 
milestone for the response to IM, whereas failure to achieve it within 18 months is 
commonly considered as suboptimal response or treatment failure, meeting the 
definition of drug resistance. PCR-negativity indicates the ultimate milestone of 
response to treatment and it is defined as complete molecular response (CMR). 
Unfortunately  even  PCR  negativity  cannot  be  a  guarantee  of  disease eradication: 
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treatment interruption in patients with minimal residual disease has led to disease 
recurrence and onset of resistance in approximately 60% of patients.
49
  
The existence  of  patients  resistant  to  TK  inhibitors  has  been  evident  since  
the introduction of the drugs into clinical practice. In contrast to chronic phase, in 
blastic phase  disease  primary   resistance  is  common  and  durable  responses  
are  the exception.
47,48,40,49  
These findings led to considerable efforts to generate a 
model of the development of resistance. Resistant cell lines were created through 
exposure to progressively higher concentrations of imatinib. The   mechanisms of 
clinical resistance to IM are generally complex and likely to be a result of 
extrinsic causes (i.e. increased plasma concentrations of α1 acid glycoprotein, 
which binds the drug and decreases its effective concentration), and/or intrinsic 
resistance to the treatment. Intrinsic resistance to IM is likely to be a multifactorial 
process and can be postulated in two distinct types: a) the leukaemic cells survive 
and proliferate independently of BCR-ABL1; b) the leukaemic cells still need 
BCR-ABL1 but somehow elude the inhibitory effect of the drug. As every TKI is 
given orally, mechanisms  identified include variations in oral bioavailability, as 
well as: plasma-protein binding; changes in  intracellular  drug  availability;  
enzymatic  inactivation;  increased  expression  of BCR-ABL1;  presence  of  the  
refractory  quiescent  stem  cells;
50   
and  changes  in expression or mutations of 
target molecule. 
 
 
 
 
I.III The problem of resistance to TK inhibitors in CML 
 
 
 
 
Several studies have shown that outcome of CML is best when IM is given in newly 
diagnosed  patients  in  chronic-phase  disease.
51,52   
Patients  transferred  to  IM  as 
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second-line therapy after  IFN failure, showed less convincing sustained remission 
rates.  Nonetheless,  a number of newly  diagnosed  patients  experience treatment 
failure. Out of the patients included in the International Randomised IFN and IM 
Study (IRIS), circa 25% ‘failed’ because of refractoriness (primary resistance), or 
lost  response  after  attainment  of  initial  response  and  progressed  (secondary 
resistance), or showed intolerance. 
In contrast to chronic phase, in blastic phase disease, primary resistance is common 
and durable  responses are the exception.
47,48,41,49  
These findings led to concerted 
efforts to generate a  model of the development of resistance. Resistant cell lines 
were created through exposure to progressively higher concentrations of imatinib. 
The mechanisms of clinical resistance to IM are generally complex and likely to be 
a multifactorial process and can be described in two distinct types: a) the leukaemic 
cells survive and proliferate independently of BCR-ABL1; b) the  leukaemic  cells 
still need BCR-ABL1 but somehow elude the inhibitory effect of the drug. As every 
TKI is given orally, mechanisms identified include variations in oral bioavailability, 
as  well  as:  plasma-protein  binding;  changes  in  intracellular  drug  availability; 
enzymatic  inactivation;   increased  expression  of  BCR-ABL1;  presence  of  the 
refractory quiescent stem cells;
50  
and  changes in expression or mutations of the 
target molecule. Each of these mechanisms of resistance to IM are distinguished and 
examined in detail below. 
 
 
 
 
 
 
 
I.III.A Increased expression of BCR-ABL1 
 
 
 
 
Mahon and colleagues
54 
showed that as the most frequent mechanism of resistance 
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in vitro is  increased expression of BCR-ABL1. This was achieved by creating a 
resistant  cell  line,  LAMA-84R,  derived  from  a  blast  crisis  CML  patient  and 
subsequently  exposed  to  increasing  concentrations  of  IM.  
In  clinical  practice increased mRNA and protein expression of BCR-ABL1 appear 
to be a less recurrent phenomenon. The chance of gene amplification is likely to be 
the result of genetic instability with a rate of  occurrence of 10
-4  
per cell division 
(against 10
-9  
per base per cell division attributed to the point mutations). This rate, 
however, is only followed in cell  lines  and  point  mutations  appear  in  practice  
as  a  more  common  cause  of resistance. In a large study of 66 patients with 
primary and  secondary resistance, only 2 of them were found presenting BCR-
ABL1 gene amplification.  Increased levels of BCR-ABL1 protein expression 
usually correlate with progressive disease and  dose escalation of IM has been 
shown to help restore responsiveness in such patients.
55 
 
 
 
 
 
 
I.III.B Drug efflux and influx 
 
 
 
 
The role of some membrane pumps among various patients has been thought as 
an aetiology  for  varying  IC50  of  IM,  resulting  in  heterogeneous  rates  of 
response. It has been quite well established that IM is a substrate for the efflux 
channel P-glycoprotein (Pgp), also called ABCB1 (ATP-binding cassette sub-family 
B member 1) and MDR1 (multidrug resistance 1).
56  
Making again use of the cell 
line  LAMA  84-R,  Mahon  et  al.  reported  an  increase  in  ABCB1  expression. 
Subsequently, by exploiting two different inhibitors of this pump, Che and Kotaki 
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managed  to  restore  sensitivity  to  IM  in  BP  samples.
57   
However,  in  follow-up 
studies, failure of attempts to demonstrate a causative role of Pgp expression levels 
in determining specific rates of clinical response to IM,
58  
raised the suspicion that 
Pgp  expression  may not  be  a  clinically relevant  marker  of  resistance  in  CML 
patients. The major group of uptake transporters belong to the solute carrier (SLC) 
super family, which includes 12 organic cation transporters (OCT). Thomas  and 
colleagues
58   
showed that the transport of IM into the cells is an active rather than a 
passive process and seems to be mediated by hOCT1 protein, an ATP-dependant 
membrane protein channel. Subsequently Crossman et al.
56
, analysing a group of 
patients who failed to achieve a minor CyR after 10 months of IM therapy, 
demonstrated reduced levels of  hOCT1  in the bone marrow. Furthermore, it was 
reported that patients presenting  the  lowest  hOCT1  activity  were  characterised  
by  a  markedly lower overall survival and progression-free survival compared 
with all the other cohorts. However, whether hOCT1 levels have a role in 
meaningful differences in the rate of clinical resistance is currently unknown. 
 
 
 
 
 
 
 
 
 
I.III.C Drug binding 
 
 
 
The serum protein α1-acid glycoprotein (AGP) has been implicated as responsible 
for IM sequestration in the plasma, this preventing the drug from reaching its target 
BCR-ABL1 kinase, as demonstrated in mouse models.
57 
However, although it was 
found that  most of the IM-treated CML patients were characterised by elevated 
plasma AGP levels and  these were slower to respond to treatment, yet binding of 
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IM to AGP has not been demonstrated in CML patients’ samples58 and AGP is now 
generally considered being an unlikely mechanism as an aetiology of IM resistance. 
 
 
 
 
 
 
 
 
 
I.III.D Clonal cytogenetic evolution 
 
 
 
 
Often  related  to  disease  progression,  clonal  cytogenetic  evolution  includes  
the acquisition  of  additional  cytogenetic  abnormalities  in  the  Ph+  chromosome  
cell population.
50  
Moreover, the  frequency of developing clonal evolution appears 
to be higher than developing ABL-kinase domain mutations, as supported by a 
study led by  Lahaye  and  colleagues  in  300  patients  in  different  CML  phases  
on  IM.
50
 
The CD34
+
/CD38
-
 population also seem the most inherently resistant of the stem 
cells to IM. Several possible explanations exist for this insensitivity, including 
over-expression of BCR- ABL1 mRNA, protein and kinase activity, as well as an 
increased expression of Pgp and a highly suppressed expression of hOCT1. Despite 
being deemed as an attractive explanation for the failure to completely eliminate all 
leukaemic cells even in the best CML responders, some contradictions remain with 
this  hypothesis. The amount of these  primitive  cells  represent  still  a  relatively  
low  number;  CD34+/CD38-  are unlikely   to   develop   point   mutations,   since   
these   occur   during   proliferation. Ultimately, quiescence cannot justify the 
significantly rapid evolution to advanced phases  after  molecular  response. A  
possible  strategy to  eradicate  this  quiescent compartment could be the 
combination of a tyrosine-kinase inhibitor with another signal- transduction 
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inhibitor with the ability to trigger the cell cycle. 
 
 
 
 
 
 
 
 
I.III.F Epigenetic modification 
 
 
 
 
Gene expression and protein function can be regulated by a balance of epigenetic 
acetylation and  methylation, respectively. Disruption of this balance can 
promote abnormal cell proliferation and resistance to apoptosis. In a recent study 
Lee and co- workers
61 
documented IM resistance of a CML cell line subsequent to 
upregulation of Class I and III histone deacetylases (HDACs) and down-regulation 
of several histone acetyltransferases (HATs). Following this, these cells were 
treated  with the histone deacetylase inhibitor SAHA (Suberoylanilide Hydroxamic 
Acid), restoring the apoptotic threshold. Although HDAC inhibitors have yet to 
be translated into clinical therapies for the treatment of IM- resistant patients, they 
are currently been studied in association with TKIs. 
Epigenetic methylation can regulate the expression of genes with tumour-
suppression and apoptotic functions. In a recent study it was shown that cell lines 
with reduced expression of the  pro-apoptotic B-cell lymphoma 2 (BCL-2)-
interacting mediator, when  co-treated  with  the   hypomethylating  agent  
decitabine,  showed  increased susceptibility to IM. Yet, whether the therapeutic 
strategy to combine a TKI with a hypomethylating agent in patients with earlier 
phase disease, can increase resistance rates, has still to be unveiled.
61 
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I.III.G. Low activity of some tyrosine phosphatases 
 
 
 
 
Down-regulation of some phosphatases is another mechanism of resistance being 
identified in CML cell lines and documented in patients. As previously discussed in 
this manuscript, STAT5 is an  important modulator of the anti-apoptotic BCL-X 
gene transcription and its constitutive phosphorylation is critical for proliferation 
of CML cells. The marked down-regulation of T cell protein tyrosine phosphatase 
(TC-PTP) in the IM resistant KTR cell line, which by having i(18)(q10) abnormal 
fusion isochromosomes lacking 18p11.2-11.3, the location of TC-PTP gene, lead to 
increased  phosphorylation levels of STAT5 and increased  resistance  to  IM.
63   
The  forced  expression  of  T  cell  protein  tyrosine phosphatase could restore 
susceptibility to IM. In another study, Neviani and co- workers
  
described in 
p210-CML the inactivation of PP2A (the tumour suppressor protein phosphatase 
2A), resulting into increased and sustained BCR-ABL1 activity. Restoring  PP2A  
activity, achieved by SET downregulation,  affected   in vitro and in vivo wild-type 
and T315I BCR/ABL leukaemogenesis by antagonising the effects of BCR/ABL on its 
downstream signal transducers and promoting BCR/ABL inactivation and proteasome-
dependent degradation,  causing growth inhibition, apoptosis stimulation, and an in 
vivo leukaemogenesis reduction of both IM-sensitive and -resistant CML cell lines 
and blast crisis patient cells.
64
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I.III.H. SFK Dependent Mechanisms 
 
 
 
Although BCR-ABL1 mutations play a  major role in IM resistance, treatment 
failure has also been  observed in patients who do not harbour BCR-ABL1 
mutations or amplification.
65  
Furthermore,  data from  expression profiling and in 
vitro analysis predict the involvement of additional genes in IM resistance and 
progression to blast crisis, although most of these genes have yet to be thoroughly 
studied or described in clinical samples of CML patients.  
The Src family kinases (SFKs) are   non-receptor, intracellular tyrosine kinases 
that regulate multiple signal-transduction pathways involved
 in cell growth, differentiation, survival, cytoskeletal organisation, migration and 
adhesion, as a result of their ability to cross-talk with a number of various classes of 
cellular receptors and many distinct cellular targets.
66   
SFKs comprise nine highly 
homologous members expressed in a tissue-specific manner with some of them been 
strongly linked to BCR- ABL1 signalling and leukaemogenesis.
67,68  
Multiple 
domains of BCR-ABL1 interact with  and  activate  SFKs  independently  of  
BCR-ABL1  kinase  activity
69,70    
and increasing evidence suggests that SFKs are 
involved in BCR-ABL-independent forms of imatinib resistance. Several SFK 
members including Hck, Lyn and Fyn, are targets of BCR-ABL1. Hck and Lyn are 
expressed and activated in the acute phase of CML patients, and their up-
regulation correlates with disease progression and resistance in patients treated with 
imatinib.
71,72 
Dai and co-workers showed the role of the SRC kinase Lyn
73  
in 
resistance to imatinib in a resistant cell line expressing low levels of BCR- ABL1   
protein   and   mRNA.   BCR-ABL1   independent   imatinib   resistance   was 
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associated with marked activation of Lyn, while t h e r e  w a s  increased 
expression of Bcl1 and reduced expression of p-Crkl. Lyn is a potentially 
important downstream target of BCR-ABL1. Activation of Lyn is associated with 
a marked increase in the levels of the anti-apoptotic protein  Bcl2.
73  
Pronounced 
increase in mitochondrial-associated Bcl2  in  these  resistant  cells  may  
contribute  to  protection  against  IM  mediated mitochondrial  dysfunction.
73   
Fyn  
is  ubiquitously  expressed  and  its  expression  is higher in blastic crisis than in 
chronic phase, and occurs in BCR-ABL1–expressing cells in vivo as well as in vitro 
at the mRNA 
74,75
and protein level. 
Thus, to overcome resistance to imatinib, which targets mainly BCR-ABL1, 
other compounds have been formulated to target activation of SFKs that is 
independent of BCR-ABL1.  Dasatinib  and  bosutinib  are dual SFK/BCR-ABL1  
inhibitors  for the treatment  of  patients  that  should  be   useful  for  imatinib-
resistant  CML.  The introduction of dasatinib or bosutinib has indeed proved 
effective and the majority of patients achieve a durable CHR. Nevertheless, some 
subjects do not respond to these second-generation TKIs (2G-TKIs). T315I is the 
main mutation in the BCR-ABL1 kinase domain that causes pan-resistance to all 
currently employed TKIs. However, the mechanism of resistance acting in the 
non-responding patients who lack identifiable BCR-ABL1 mutations is still 
essentially unknown. 
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I.III.I BCR-ABL1 Kinase Domain Mutations 
 
 
 
One of the most prevalent mechanisms leading to reactivation of BCR-ABL1 is 
point mutations  throughout the ABL1 kinase domain and t h i s  might be the 
cause of resistance  in  some  cases.  The  association  between  BCR-ABL1  
kinase  domain mutations and resistance to TKIs will be thoroughly discussed in 
the next chapter. 
 
 
 
 
 
 
 
 
 
 
 
I.IV. Mutations within the ABL kinase domain 
 
 
 
 
As earlier described in this thesis, the mechanism of acquired resistance has 
been attributed to  various possible mechanisms, but certainly the best 
understood and most commonly documented  in clinical practice is the selection 
of a Ph+ clone bearing a BCR-ABL1 kinase domain mutation.
76 
Up to now, 
more than 50 mutants have been reported,
77,78,79,80 
with some at a higher frequency 
than others: 15 amino- acid changes account for over 85% of the detected 
mutations. 
 
Most of the characterised mutations affect specific BCR-ABL1 KD residues that 
form  hydrogen  bonds  or  hydrophobic  interactions  with  IM,  hence  leading  
to structural  changes  such  that  IM  can  no  longer  displace  ATP.  These kinds  
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of mutations, hitting amino acid positions involved in the direct bond with IM, 
such as Y253, T315 and F317, lead usually to strong IM  resistance. A second 
group of mutations is represented by the capacity to shift the equilibrium of the 
KD toward an active state, thus obstructing IM access to the ATP-binding site; 
this group includes amino acid exchanges at H396, M388, S348 and M351. 
Alternatively, mutations can further be  clustered according to their localisation 
among different functional domains. The recognised  classification for the kinase 
domain motifs describes 5 domains: the P loop (also called ATP phosphate-
binding loop, including amino acids 248 to  255,  the  gatekeeper  region  
(occupying  residues  299-317),  the  catalytic domain (spanning 351-359 AA 
residues), the activation loop (A loop, including AA 384-396), and the C-loop 
(also called C-terminal lobe, 453-486) (fig.1.3). It has been documented
81 
that 
mutations affecting P-loop and gatekeeper regions (with the T315I in spotlight) 
develop more frequently (fig.1.4) This categorisation, however, does not allow an 
estimate of the degree of resistance, and in fact the class of P loop mutations  
clusters  amino acidic  exchanges  with  moderate  (G250A,  Q252H,  and E255D) 
to high IM resistance  (G250E, Y253H, E255V/K). Even mutations occurring in 
the same residue – e.g. E255, with E255D, E255K, and E255V – can confer 
different TKI sensitivity.
82,83 
It seems that some AA substitutions may occur in 
particular CML stages; for example mutations M244, L248, F317, H396, and 
S417 are more likely to be detected in chronic-phase disease, whereas Q252, 
Y253, E255, T315, E459 and F486 are associated with advanced phases.
50 
The 
probability of  reporting  mutations,  however,  increases  with  disease  
progression  and  with advanced phase disease. In vitro studies have reported that 
some mutants (e.g. T315I and E255K) cause one- or two-log increase to their 
IC50 for  IM, compared with wild type BCR-ABL1, hence identification of the 
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precise mutation may  have major  clinical  relevance.  Some  mutants,  such  as  
T315I  and  E255K,  retain insensitivity to IM at clinically available doses, 
whereas others, such as M351T or Y253F show  partial sensitivity to IM. 
Specifically, the mutation at position 315 (T315I)  is  notorious  for  conferring  
nearly  complete  clinical  resistance  to  all currently approved ABL-kinase 
inhibitors  and is mostly detected in advanced phases. Threonine 315 is located 
at the “gatekeeper”  residue  in the centre of the ATP-binding cleft, forming a 
crucial hydrogen bond with IM; the T315 side chain controls the binding of IM to 
the hydrophobic cage that is close to ATP-binding domain. The absence of an 
oxygen atom in the substituted isoleucine alters the three-dimensional structure of 
the hydrophobic cage, hence preventing bond  formation with IM and the more 
recent kinase inhibitors nilotinib and dasatinib.
76,84 
Tyr 253 makes only a weak 
van der Waals contact with IM, but forms a water-mediated hydrogen bond with 
the side chain of Asp 322, folding the P  loop down and increasing surface 
complementarity; substitution of Tyr with Phe would not be described as 
interfering directly with drug binding, but might decrease the affinity of an 
induced-fit interaction of IM with the ATP-binding site. Mutations of other 
residues in the ATP-binding site including conversions of Glu 255 to Lys or Val 
lead to enzymes that are insensitive to IM and  have been reported  in  patients  
with  advanced  CML. (Sergei  Roumiantsev,  2002)  A  strong association of the P 
loop mutations with a poor prognosis has been documented by Branford and  
colleagues in both chronic and accelerated phases’ CML patients. (Brandford, 
2004) 
The functional relevance of all these findings is still unclear, especially in terms 
of whether some amino acid substitutions are responsible for disease evolution, by 
conferring, for example, a proliferation advantage to the mutated cells, or whether 
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they simply act as a surrogate marker of the  increased genomic instability 
typical of CML advanced  phases.  Several  laboratories  have   demonstrated  
the  occurrence  of mutations  even  in  untreated  patients,  and it  has  been  
suggested  that  the  selective pressure applied by IM favours the outgrowth of 
pre-existing resistant clones.
85
  Therefore, early detection of mutations in pre-TKI 
treatment patients could help to identify  cases  at  high-risk  of  resistance  and  
to  select  beforehand  the  optimal treatment.   Biochemical   and   biological   
assays   conducted   by   Griswold   and colleagues
86  
studied five common KD 
mutations in distinct KD regions, including Y253F and E255K (within the P 
loop), T315I  (belonging to the gatekeeper region), M351T (within the catalytic 
domain), and H396P (found in the activation loop), showing that different 
mutations not only are characterised by distinctive resistance  to  IM,  but  also  
feature  specific  growth  and  proliferative  capability. Exploiting the BaF3 cell 
line, these assays described the proliferative ability of the  different clones in the
 following order: Y253H>E225K>WT>T315I>H396P>M351T. These  
findings  may  represent  an important clarification in understanding the role of 
some IM-resistant mutations in disease progression from chronic to accelerated 
phase or blast crisis. Transforming capabilities correlated with kinase activity only 
for some mutations. Compared with the wilde-type BCR-ABL1, Y253F was noted 
to produce enhanced kinase activity (gain of  function)  with  E255K  causing  
comparable  activity.  On  the  other  hand,  the remaining three point mutations 
lead to loss-of-function variants, by affecting the enzymatic function, maybe due 
to a specific selection exerted by the drug. 
87 
These data  have  however  found  
discrepancy with  the  results  published  by  Skaggs  et al,(2006)  following  
investigation  of  the  correlation  of  oncogenicity  and  kinase activity in regard 
to seven  frequent and clinically relevant KD mutants T315I/A, E255K/V, 
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Y253H, M351T, and F317L, together with wild-type p210-BCR-ABL1. In most 
cases oncogenic potency was associated with kinase activity. An interesting 
exception was represented by T315I, which showed greater potency  capacity but 
reduced kinase activity in comparison with wild-type BCR-ABL1. Through a 
global phosphoproteome analysis, revealing the tyrosine phosphorylation profiles, 
it was possible to identify a unique phosphosubstrate signature associated with 
each drug- resistant point mutation.  This indicates that a single aminoacid 
conversion in the kinase domain can produce specific effects on substrate 
recognition. Three groups appeared from this analysis. T315I and E255K  
systematically showed a 10–20% increase in oncogenicity relative to wild-type 
BCR-ABL1, demonstrating that they are indeed gain-of-function mutants as 
suggested by clinical evidence of pre-treatment detection. The second group 
emerging from this analysis contained Y253F and E255V, which displayed 
transforming activity similar to wild-type p210. The final group  contained  four 
point KD mutations (Y253H, M351T, F317L, and T315A) with consistently 
reduced potency. Examination of the respective kinase activity of these  mutants  
showed  that  with  the  exception  of  M351T  and  T315A,  having substantial 
reduced kinase activity, and the  two mutants E255K and Y253F, with stronger 
activity, most kinase inhibitor-resistant mutants  exert comparable kinase activity 
to wilde-type BCR-ABL1. To determine the correlation between kinase activity 
and oncogenicity, Vmax  (maximum reaction rate) was plotted versus the 
oncogenicity score that resulted in the bone marrow assays. These two variables 
were closely related for most of the TKI- resistant mutants with one  notable 
exception: the T315I mutant showed a 20% greater potency than wild-type 
p210 in bone  marrow transformation despite a nearly 50% reduction in Vmax. 
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Fig.1.3 Schematic representation of the BCR-ABL1 KD, with the P-loop, Catalytic domain, 
Activation loop and C-loop. The AA changes identified so far are shown. Fig. adapted from 
Soverini et al., Clinical Chemistry, 2004. 
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                                                                                                             J Apperley, The Lancet, 2007 
 
 
 
 
 
Fig.1.4 Incidence  of  mutations in relation to their  domain clustering and their  absolute 
frequency. (A) Incidence of detected tyrosine-kinase mutations by absolute number and by 
percentage of total. The seven most frequent aminoacid substitutions of BCR-ABL1 KD are 
depicted in red. Specific domains of the kinase domain are indicated as P-loop (p), gatekeeper region 
(b), catalytic domain (c) and activation loop (a). (B) Incidence of the same mutations in order of 
frequency. 
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II. Aims 
 
 
 
 
 
The overall aims of this thesis have been: 
1) Establishment of novel methodologies for the detection of mutations that 
satisfies the criteria of specificity, sensitivity and rapidity in relation to the data 
from existing literature, carrying out a comparative test with the well-known 
direct sequencing technique. 
 
 
 
2) Systematic evaluation of the mutations arising after treatment with imatinib 
and second- generation tyrosine kinase inhibitors (2G-TKIs) dasatinib, nilotinib 
and bosutinib. 
 
 
 
3) I have hypothesised that the ineffectiveness of treatment with dual 
SFK/BCR-ABL inhibitors dasatinib and bosutinib might be due to the 
introduction of point mutations within the tyrosine-kinase domain of one or other 
of the three Src kinases that have been implicated in the development and 
progression of  CML:  Hck, Lyn, and Fyn. Point mutations in the kinase domain 
of these Src kinases might result in a  change of structure that impeded the 
contact of the drug with the Src kinases in a manner analogous to BCR-ABL1 
kinase domain mutations. 
Consequently, the aims of this thesis have been the identification of the patients 
who did not respond to  dual  SFK/BCR-ABL inhibitors dasatinib and bosutinib 
and did not present BCR-ABL1 kinase domain mutations, and an investigation 
into whether SFK KD mutations played a causal role for resistance. 
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II. Patients and Methods 
 
 
 
 
Patients characteristics and subgroups 
 
 
II.I Patients and Samples 
 
 
 
 
The samples used in this study were acquired from routine blood samples 
provided by patients  with CML. The majority were obtained during hospital 
visits to the Hammersmith Hospital and  a  small proportion was sent from the 
patients’ local hospitals. All patients gave informed consent  for the use for 
research of material remaining from routine blood testing. 
Bone marrow morphology and cytogenetics were assessed by other members of 
the Department at diagnosis and then every 3 months until patients achieved 
complete cytogenetic  response  (CCyR).  Thereafter  patients  were  monitored  
by  real-time quantitative PCR and annual bone marrow examinations. 
Response  to  therapy  was  assessed  according  to  the  recommendations  from  
the European  LeukemiaNet. Complete haematologic response (CHR) was 
defined as blast count of less than  10% in the bone marrow, no blasts or 
promyelocytes in peripheral blood, neutrophil count of at least 1.5 x 10
9
/l with 
<5% immature forms (excluding  promyelocytes  and  blasts),  platelet  count  up  
to  450  x  10
9
/l,  and  no evidence of extramedullary involvement. Partial 
haematologic response (PHR) was defined as blast count on blood and bone 
marrow less than 15%, neutrophil count, at least 1 x 10
9
/l and platelet count at 
least 20 x 10
9  
/l (without platelet transfusion and without evidence of bleeding), 
and no evidence of extramedullary involvement. CCyR  was  defined  either  by  
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the  failure  to  detect  any  Ph-chromosome-positive metaphases in  two 
sequential bone marrow aspirates with at least 20 metaphases examined, or by a 
2-log reduction in BCR-ABL1 transcript levels from diagnosis or the laboratory-
specific standard baseline.  Major cytogenetic response (MCyR) was defined by 
combining the number of complete and partial cytogenetic responses (1 - 35% 
Ph-positive metaphases). Cytogenetic relapse (loss of CCyR) was defined by the 
detection of  one or more Ph-positive marrow metaphases, also confirmed by a 
subsequent study. Bone marrow  examination was triggered by a rise in BCR- 
ABL1 transcript numbers to a level consistent with cytogenetic relapse. 
Molecular  response  was  evaluated  using  RQ-PCR  methodology.   BCR-
ABL1 transcript levels  were expressed as a percentage ratio of BCR-ABL1 to 
ABL. A reduction  in  BCR-ABL  transcript  levels  of  >3  log  (1000-  fold  
reduction)  from diagnosis  or  the  laboratory-specific  standard  baseline  was  
defined  as  a  major molecular response (MMR). A complete molecular 
response (CMR) was defined as an undetectable BCR-ABL transcript level by 
RQ-PCR confirmed  by a negative nested PCR whose lowest limit of 
detectability is 10
–6
 and that I carried out myself. At 3 months of treatment 
optimal response, suboptimal response and failure were defined  as  follows:  
optimal  response  featured  a  CHR  with  at  least  a  minor cytogenetic response 
(36-65%  Ph-positive metaphases). Suboptimal response was defined as a CHR 
associated with failure in the cytogenetic response (meaning that more than 95% 
of metaphases are Ph+). Therapeutic failure was considered when  CHR response 
had not been achieved. 
 
Between November 2007 and December 2010, 269 adult patients with BCR- 
ABL1 positive  CML were treated at the Hammersmith Hospital London (HH) 
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or referred  at  the  latter  from  external  institutions.  Imatinib  was  used  as  
front-line therapy for 256 patients, while i t  was administered as  second-line 
therapy to 8 patients post  failure  with  interferon  or  hydroxyurea (table 2A).  
Dasatinib  was  chosen  as  front-line treatment for 5 patients. Treatment with at 
least one of the three second-generation tyrosine kinase inhibitors (dasatinib, 
nilotinib, bosutinib) as second- or  third-line therapy was received by 154 
patients. Two patients received homoharringtonine as second- or third-line 
treatment. Details of chosen treatment for the 269 patients and their clinical 
characteristics are shown in table 2A and 2B. Bone marrow morphology and 
cytogenetics were assessed at diagnosis and then every 3 months until patients 
achieved CCyR. Cytogenetic response  was defined as complete by the failure 
to detect any Ph-positive metaphases and it was confirmed when noted on two 
consecutive  bone marrow assessments at least 28 days apart; major cytogenetic 
response  (McyR) was defined by including complete and partial cytogenetic 
responses (≤35% Ph-positive metaphases). Cytogenetic relapse (loss of CcyR) 
was defined by the detection of one or more Ph-positive marrow metaphases, also 
confirmed by a subsequent study. 
Further object of study was a second group, originated from the cohort of the 269 
patients, which included  patients  on  2G-TKI  dasatinib  and/or  bosutinib  
showing  resistance  to treatment  without presenting  BCR-ABL1  mutations.  
This  group  was enrolled in the investigation for the presence of  mutations 
hitting the kinase domain of any of the 3 SFK genes Fyn, Lyn  and  Hck as a 
cause of treatment resistance. Combination of the results from the two groups of 
patients have been further used to establish  new  methodologies for mutation 
detection (i.e. pyrosequencing and d- HPLC) and compare them with the current 
gold standard (direct sequencing). 
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Table 2A: list of different therapies used on the whole cohort of 269 patients. List of the 
various treatments (each specified with alphabetical letter) and numbers of respective treated 
patients. 
 
 
Treatment group (269 pts)                 
 No. of 
pts 
A: IM 106 
B: IM + DASA 59 
C: IM + NILO 37 
D: IM + NILO + HHT 1 
E: IM + DASA + NILO 31 
F: IM + NILO + DASA 11 
G: IM + DASA + HHT 1 
H: IM + HHT + NILO + DASA 1 
I: IM + DASA + BOSU 1 
J: IM + DASA + BOSU + NILO 1 
K: IM + NILO + BOSU 1 
L: IM + BOSU 3 
IM: IM + INF 2 
N: INF + IM 1 
O: INF + IM + DASA 2 
P: INF + IM + HU + DASA + NILO 2 
Q: HU + IM 1 
R: HU + IM + NILO 1 
S: HU + INF + IM + DASA + NILO 1 
T: IM + DASA + HU 1 
U: DASA 5 
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Table 2B. Summary of characteristics, dosing and response to treatment for the cohort of 269 patients. Patients have been clustered only accordingly to the type of TKI 
treatment received (independently of the type of administered non-TKI treatment). Patients who were administered single or multiple TKI-agent treatment were clustered 
together with patients who received the same TKI treatment combined with non-TKI agents (INF, HHT, HU).  
 
 
 
 
  
 
  no. (%) 
 
 
  Male, no. (%) 
 
 
Median age, y 
(range) 
Median 
disease 
duration, mo 
(range) 
 
 
Best response 
achieved 
 
IM intolerant 
or resistant? 
no. (%) 
 
Stem cell 
transplants? 
no. (%) 
INF and/or 
HU received 
prior IM? no. 
(%) 
HU or HHT or 
INF received 
post IM? 
no. (%) 
 
  TOTAL 
 
  269 (100) 
 
  158 (59) 
 
  55 (18-91) 
 
  58 (3-241) 
 
  MMR 
 I: 39 (14) 
 R: 103 (38) 
 
  301 (11) 
 
  6 (4) 
 
  7 (3) 
   
  IM 
 
  110 (41) 
 
  69 (63) 
 
  55 (18-91) 
 
  67 (4-92) 
 
  MMR 
 I: 2 (2)   
 R: 35 (32) 
 
  8 (7) 
 
  2 (2) 
 
  3 (3) 
 
  IM + DASA 
 
  61 (23) 
 
  37 (60) 
 
  56 (21-88) 
 
  49 (3-125) 
 
  CCyR 
 I: 20 (33)  
 R: 18 (30) 
 
  7 (11) 
 
  2(3) 
 
  2(3) 
 
  IM + NILO 
 
  33 (12) 
 
  19 (58) 
 
  52 (24-80) 
 
  40 (4-198) 
 
  CCyR 
 I: 5 (15) 
 R: 19 (58) 
 
  2 (6) 
 
  1 (3) 
 
  1 (3) 
 
  IM+ BOSU 
 
  3 (1) 
 
  2 (67) 
 
  62 (35-80) 
 
  38 (9-41) 
 
  MCyR 
 I: 0 (0)  
 R: 1 (33) 
 
  1 (33) 
 
  0 (0) 
 
  0 (0) 
  IM + DASA +  
  NILO 
 
  37 (14) 
 
  21 (57) 
 
  60 (38-77) 
 
  54 (4-241) 
 
  MCyR 
 I: 9 (24)  
 R: 23 (62) 
 
  9 (24) 
 
  3 (8) 
 
  0 (0) 
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Continued (table 2B.) 
 
 
 
 
  
 
  no. (%) 
 
 
  Male, no. (%) 
 
 
Median age, y 
(range) 
Median 
disease 
duration, mo 
(range) 
 
 
Best response 
achieved 
 
IM intolerant 
or resistant? 
no. (%) 
 
Stem cell 
transplants? 
no. (%) 
INF and/or HU 
received prior 
IM? no. (%) 
HU or HHT or 
INF received 
post IM? 
no. (%) 
  IM + NILO +   
  DASA 
 
  13 (5) 
 
  7 (54) 
 
  40 (34-79) 
 
  36 (5-56) 
 
  MCyR 
  I: 3 (23)     
R: 7 (54) 
 
  3 (23) 
 
  0 (0) 
 
  1 (8) 
  IM + DASA +    
  BOSU 
 
  1 (<1) 
 
  1 (100) 
 
  35 
 
  71 
 
  MCyR 
 
  R: 0 (0) 
 
  0 (0) 
 
  0(0) 
 
  0 (0) 
  IM + DASA +    
  BOSU + NILO 
 
  1 (<1) 
 
  1 (100) 
 
  79 
 
  112 
 
  CHR 
 
  R: 0 (0) 
 
  0 (0) 
 
  0 (0) 
 
  0 (0) 
  IM + NILO +    
  BOSU 
 
  2 (1) 
 
  1 (50) 
 
  51 (44-58) 
 
  13 (9-17) 
 
  MCyR 
 
  R: 0 (0) 
 
  0 (0) 
 
  0 (0) 
 
  0 (0) 
 
  DASA 
 
  5 (2) 
 
  4 (80) 
 
  68 (63-73) 
 
  22 (5-68) 
 
  MMR 
 
  NA 
 
  0 (0) 
 
  NA 
 
  NA 
 
 
 
Abbreviations:  IM,  DASA,  BOSU  and  NILO  indicate  respectively  imatinib,  dasatinib,  bosutinib  and  nilotinib;  CP  indicates  chronic  phase;  AP, accelerated  
phase; BC, blastic crisis; CHR, complete haematological response; MCyR, major cytogenetic response; CCyR, complete cytogenetic 
response;  MMR  major  molecular  response.  NA:  not  applicable.  Percentages  have  been  referred  to  the  total  cohort  of  269  patients. 
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II.I.I  Patients  in  the  first  and  second  generation  tyrosine  kinase 
inhibitors study 
 
 
 
 
Object of this study was a group of 269 patients that included: 
 
 
1. 110 patients that received imatinib as single tyrosine kinase inhibitor. 
 
2. 156 patients who experienced imatinib resistance or intolerance and were 
therefore administered at least one second-generation TKI. 
3. 5 patients who received dasatinib as frontline. 
 
 
Depending on patients’ toxicity levels and disease progression, imatinib was 
administered at  a dose between 400 and 800 mg once daily; dasatinib was 
administered at a dose between 70 and 100 mg twice daily, nilotinib between 300 
and  500 mg  twice  daily  and  bosutinib  between  400  and  600mg  once daily. 
Dosage was however reduced in case of presence of myelosuppression or other toxic 
effects. Of the 110  patients receiving IM as single TKI, two had been treated with 
IM as first line treatment followed by INF, and two had received IM   as   second-line   
therapy   after   failure   with   INF or   HU.   Patients’ characteristics  are  
summarised  in  Table  2B.   
Each of the 296 patients had sequential samples for BCR-ABL1 kinase domain (KD) 
mutations analysis and were systematically screened for KD mutation by direct 
sequencing. When a mutation was detected and there was availability of three  or  
more  previous   sequential  samples  (range  3–10)  collected  during treatment 
administration, pyrosequencing was carried out to track back mutation appearance and 
quantify its levels. D-HLPC was also  conducted on a limited number (40) of both 
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on mutated and un-mutated samples to test sensitivity and specificity of this 
methodology. 
Additionally, patients on 2G-TKIs dasatinib and bosutinib who had been found being 
resistant to therapy without harbouring BCR-ABL1 KD mutations, were selected for 
mutation analysis within the SFK genes Fyn, Lyn and Hck as reported in details in 
chapter II. 
 
 
 
 
 
 
 
 
 
 
 
II.II RNA extraction 
 
 
 
A white cell pellet was prepared from 10 to 20 ml peripheral blood and/or from 2 to 3 ml of 
marrow aspirate, both of which had been collected into EDTA or preservative- free heparin 
and treated with  an ammonium chloride based red cell lysis solution according to 
standard operating procedures in the laboratory. The white cells were then suspended in 1 
ml of guanidine isothiocyanate (GTC) buffer and homogenised using blunt-nosed needle 
sheering.  Total RNA from peripheral blood, bone marrow and cell harvest samples was 
extracted  using the RNeasy (Qiagen, Crawley, UK) mini kit in accordance with the 
manufacturer’s  instructions. One third of the GTC solution was used for RNA extraction 
by an ion exchange column chromatography and centrifugal force. The step by step 
procedure is described below. 
 
1. GTC lysates were thawed (stored at -20
o
C) for RNA extraction. 
 
2. 350µl of 70% Ethanol was transferred into appropriately labelled 1.5 ml micro- 
centrifuge tubes using 1000 ml plugged tip. 
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3. On thawing, GTC was vigorously vortexed one at a time. 
 
4. 350µl of GTC lysate was transferred to appropriately labelled 1.5 ml micro- 
centrifuge tubes. 
5. 700µl suspension was transferred to an appropriately labelled RNeasy spin 
column. 
6. In addition to the samples, ethanol was included as blank control, i.e. add 
 
700µl of 70% ethanol to a separate spin column and proceed as per patient sample. 
 
7. The mixture was incubated at room temperature for 30 min. 
 
8. The columns were centrifuged for 15 sec at 8000 x g. 
 
9. The flow-through was discarded from the collection tubes. 
 
10. 650µl RW1 Buffer (Qiagen RNeasy Kit) was transferred to the spin columns and 
centrifuged for 15 seconds at 8000 x g and the flow-through was discarded. 
11. 500µl RPE Wash Buffer (Qiagen RNeasy Kit) was transferred to the spin 
column  and  centrifuged  for  15  seconds  at  8000  x  g  and  the  flow-through  was 
discarded and the columns placed into a new collection tube. 
 
12. 500µl RPE Wash Buffer was added to the spin columns and centrifuged for 2 
minutes at 15000 x g. 
13. The flow-through and the collection tubes were discarded. 
 
14. The columns were placed upside down onto tissue paper in the hood, and the lids 
were kept  closed for 2 minutes. This allowed any residual 70% ethanol at the bottom of 
the column to evaporate. 
15. The columns were transferred to new labelled, 1.5ml micro-centrifuge tubes. The 
lids of the spin columns were opened slightly, and were left for approximately 
20 min. This will allow any remaining 70% ethanol present within the spin columns to 
evaporate. 
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16. 25µl of RNase-free water was applied to the centre of each column. 25µl of water 
was also set aside into a 1.5ml micro-centrifuge tube which was used later as a control for 
subsequent cDNA synthesis. 
17. The RNA was eluted from the membrane by centrifuging for 2 minutes at 
 
15000 x g. 
 
18. Each spin column was removed and discarded. 
 
19. Before discarding the pink Qiagen columns, a RNA sample for the reverse 
transcriptase (RT) negative control was extracted. RT negative sample is prepared by 
eluting with 25 µl of RNase free water through one of the patients’ Qiagen column, 
selected  randomly,  from  which  RNA  had  already  been  eluted  once.  This  “RT- 
Negative control” was then treated as per other RNA samples. However, cDNA mix added 
to this “sample” was void of RT enzyme. 
20. In addition to the samples, cDNA synthesis should also include the following 
blank controls: 
(a) 70% Ethanol control from the RNA extraction protocol. 
(b) Sterile water control (25µl), an aliquot of sterile water set aside from the RNA 
Extraction protocol. 
(c) GTC control saved from the sample processing. 
(d) RT Negative control. 
21. The RNA was incubated at 65
o
C for 10 minutes. This is to ensure the RNA is 
linear, and any secondary structure is denatured. 
22. The tubes were transferred to a micro-centrifuge and pulse spun to collect the 
contents  to   the   bottom  of  the  tube.  Then  the  tubes  were  transferred  to  ice 
immediately, to avoid formation of RNA secondary structures. 
23. One cDNA mix (see appendix 1) was thawed per 10 samples (including the blank 
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controls)  at room temperature.  For more than 10 samples, the aliquots of cDNA mix 
were thawed into a single 1.5ml micro-centrifuge tube. 
24. 6µl RNAsin (Ribonuclease Inhibitor) (per 10 samples) was added to the cDNA 
 
mix and vortexed briefly. 
 
25. 21µl of cDNA mix was taken and added to the non-template control (NTC) 
 
only. 
 
26. 12µl Moloney Murine Leukaemia Virus Reverse Transcriptase (M-MLV) RT (per 
10 samples) was added to the remaining cDNA mix and vortexed briefly. 
27. 21µl of cDNA mix was transferred to each of the other samples/controls (ie. not 
NTC tube). 
28. Each tube was incubated at 37
o
C for 2 hours. 
 
29. The mixture was incubated at 65
o
C for 10 minutes to inactivate the reverse 
transcriptase. 
30. The cDNA was stored at -70
o
C. 
 
 
 
 
All BCR-ABL1 transcript samples were tested by real-time quantitative polymerase chain 
reaction for ABL and BCR-ABL amplification as part of the MRD monitoring procedure. 
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II.III PCR amplification 
 
 
II.III.A. BCR-ABL1 KD PCR amplification 
 
 
 
 
A two-step PCR reaction to amplify BCR-ABL1 kinase domain was carried out on at least 
one sample of all the 269 patients. In the first round, the normal ABL allele was excluded 
from mutational analysis by amplifying a BCR-ABL1 amplicon from exon 13 of the BCR 
gene to exon 10 of the ABL gene. This was obtained by adding 4µl of cDNA to a 20 µl 
master mix including forward primer B2A (600nM), which anneals in BCR exon b2/e13, 
and reverse primer JamR (600nM) which anneals at the junction of ABL exon 9 and 10  
(fig.2.1) (Primers sequences are shown in table 2C).  The resultant amplicon was then 
subjected to nested primer PCR by adding 2µl of first step PCR product to a 60µl 
reaction  containing  primers  NTPB+  and  NTPE-,  in  order  to  amplify  an  863bp 
fragment  containing  the  entire  ABL1  kinase  domain  for  direct  sequencing  (see 
appendix 2). To enable pyrosequencing, aliquots of the same 1
st 
round PCR amplicon were  
also  subjected  to  amplification  using  biotinylated  primers  to  generate  PCR products  
containing the putative point mutation identified in previous samples by direct 
sequencing.  Specificity and efficiency of the amplification were assessed by 
electrophoresis of a 7µl PCR product aliquot on a SYBR Safe-stained 1.7% agarose gel   
in   TBE   buffer.   The  biotinilated   products   were  tested   for  mutation   by 
pyrosequencing, described in detail later in this chapter. 
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II.III.B. SFK KD PCR amplification 
 
 
 
 
In order to amplify FYN-, LYN-, and HCK-KD, a single-step PCR was carried out on at 
least one  sample of all the patients refractory to 2G-TKIs dasatinib and/or bosutinib 
and assessed as  BCR-ABL1 mutation negative. Amplification of FYN- kinase domain 
was obtained by using  forward Fyn_F (400nM) and reverse Fyn_R (400nM)  primers,  
respectively  annealing  in  FYN   exon  6  and  FYN  exon  11. Amplification of LYN-
kinase domain was obtained by using primers Lyn_F (400nM) and  Lyn_R (400nM), 
respectively,  annealing in LYN exon 7 and LYN exon 12. Amplification  of  HCK-
kinase  domain  was  obtained  by  using  primers  Hck_F (400nM) and Hck_R (400nM), 
respectively, annealing in HCK exon 8 and HCK exon 11 (primer sequences in table 2D; 
de t a i l s  o f  PCR reac t ion  in  Appendix 3). The resultant amplicons containing the 
kinase domain had lengths of 902 bp for FYN, 894 pb for LYN and 895 bp for HCK, which 
were then subjected to direct sequencing. 
 
 
 
 
 
 
II.IV Direct Sequencing 
 
 
 
 
The BCR-ABL1-KD and FYN-, LYN- and HCK-KD PCR amplified products from each 
individual were analysed and if a single amplicon was observed the remaining PCR  
products  were  sequenced  directly  in  a  Sanger’s  dideoxy  chain-termination reaction 
using a Big-Dye ABI 3130 sequencer (Applied Biosystems, Foster City, USA). 
However, if multiple bands were observed following the gel electrophoresis, the PCR 
fragment containing the ABL1-, FYN-, LYN- or HCK-KD, respectively for BCR-ABL1, 
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FYN, LYN and HCK genes, was isolated by excising the specific band from the gel and 
purified using commercially available gel purification kit (QIAquick PCR Purification Kit; 
Qiagen, UK) according to manufacturer’s instructions. A 30µl aliquot of each reaction was 
primed with specific pairs of oligonucleotides spanning the domain of interest, whose 
sequences are reported on tables 2C and 2D. All PCR amplicons, before being subjected 
to direct sequencing, were purified using BigDye XTerminator Purification kit (Applied 
Biosystem, Foster City, USA) in accordance with  manufacturers’ instructions. The 
Sanger’s  dideoxy-chain terminator reaction was then obtained using a Big-Dye ABI 310 
sequencer (Applied Biosystems, Foster City, USA). 
In each case the sequences obtained were respectively  compared with the published 
ABL1 type 1a  sequence (GenBank M14752), FYN (Ensembl ENST00000354650), LYN  
(Ensembl  ENST00000519728)  and  HCK  (Ensembl ENST00000375852), using  
SEQMAN  software  (DNASTAR,  Inc.,  Brighton,  MA).  All  observed  base substitutions  
were confirmed both by running in duplicate the PCR product and performing sequence 
analysis on both strands for each fragment. 
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Fig 2.1. Schematic representation of the BCR-ABL1 region studied by direct sequencing and 
pyrosequencing 
The green and blue blocks represent BCR and ABL1 genes and their respective exons joined together and 
constituting the BCR-ABL1 fusion gene. Exterior primers B2A and JamR were used to amplify through PCR 
reaction the kinase domain of BCR-ABL1 and to exclude the normal ABL1 from  mutation analysis. Interior 
primers NTPB+ and NTPE- were used for amplification of the kinase domain in the second round of the 
nested PCR to produce an 863 bp fragment. To sequence the kinase domain ABLKF, ABLKR, NTPB+ and 
NTPE- primers were used. The primer pairs of P Loop, 315, 41, 9 and C here represented in different colour, 
were used to amplify various fragments of the KD in different second steps of nested PCR 
reactions which were used for pyrosequencing. 
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Table 2C: Sequence of the primers used for first-step PCR, nested PCR, direct sequencing 
 
and pyrosequencing of BCR-ABL1. 
 
 
 
 
     Primer name     5’-to-3’ sequence 
 
 
 
 
B2A 5‘-TTCAGAAGCTTCTCCCTGACAT-3‘  
JAMR 5‘ GTACTCACAGCCCCACGGA-3‘ 
NTPB+ 5‘-AAGCGCAACAAGCCCACTGTCTAT-3‘  
NTPE- 5‘-CTTCGTCTGAGATACTGGATTCCTG--3‘  
ABLKF 5‘-AACGCCGTGGTGCTGCTGTAC-3‘ 
ABLKR 5‘-CAGTTTCGGGCAGCAAGATC-3‘ 
ITKE 5‘-CTGGAACATTGTTTCAAAGGCTTGGT-3‘  
P Loop-F1 5‘-TACGACAAGTGGGAGATGGA-3‘ 
P Loop-R1 5‘-GCCACCGTCAGGCTGTATTT-3‘ 
253+315-F 5‘-CGCAACAAGCCCACTGTC -3‘ 
41-F 5‘-GTTGTACAAGGCCACTCAGATCTCGT-3‘ (Biotinylated) 
41-R 5‘-TCTCGGTGCAGTCCATTT-3‘ 
315F                                               5‘-GCCGTGAAGACCTTGAAGGA-3‘ (Biotinylated) 
315R 5‘-CCAGGAGGTTCCCGTAGGTC-3‘  
C-F 5‘-TTACCCGGGAATTGACCTGT-3‘ (Biotinylated) 
C-R 5‘-TGTTTCAAAGGCTTGGTGGA-3‘ 
F9  5‘-CTAGAGATCTTGCTGCCCGAAACT-3‘ (Biotinylated) 
R9                                                    5‘-GACAGGTCAATTCCCGGGTAA-3‘ 
SNP-1-2                                          5‘-CACCCTGAAGCACAA-3‘                                                                                                              
SNP-2-9                                          5‘-GAACGCACGGACATC -3‘ 
SNP-231                                          5’-CATCTCCCACTTGTCG -3’ 
SNP-253/255                                   5’-CTGGGCGGGGGCCAG -3’ 
SNP-276                                          5‘-TGAAGACCTTGAAGGAG -3‘ 
SNP-299                                          5’-TTCTCTGGGCAGCCT -3’ 
SNP-311                                          5‘-GAACTCAGTGATGATATAGA -3’ 
SNP-315/317                                   5’-CCCCCGTTCTATATCA -3’ 
SNP-351                                          5‘-CCAAGATCTCTGTGGATGA-3‘ 
SNP-359                                           5‘-CAAGATCTCTGTGGATGA -3‘ 
SNP-364                                          5’-AGTTTCGGGCAGCAA -3’ 
SNP-384                                          5’-TGTCCCCTGTCA -3’ 
SNP-396                                         5’-AACTTGGCTCCAGCA -3’ 
SNP-417 5‘-GACGTCGGACTTGATG -3‘  
SNP-438 5‘-CCAATTCCCGGGTAAG-3‘  
SNP-453 5‘-CCATGCGGTAGTCCT-3‘ 
SNP-459                                         5‘-CCTTCTGGGCGCT -3‘ 
SNP-462                                         5’-TTCTCTGGGCAGCCT -3’ 
SNP-486 5‘-CTTGGTGGATTTCAGC-3‘ 
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Table 2D: Sequences of primers used for PCR and Direct Sequencing of SFK genes HCK, 
 
LYN and FYN. 
 
 
 
 
    Primer name    5’-to-3’ sequence 
 
 
 
 
 
H_F                                       5’-GAA CGA CGG GCT CTG CCA GA -3’ 
H_R                                       5’-TCA TGG CTG CTG TTG GTA CT -3’ 
s_HF                                      5’-AAA AGT GAT GAG GGC AGC AA -3’ 
s_HR                                     5’-CAA AGG ACC AGA CGT CTG ACT -3’ 
L_R                                        5’-CCA ATC TTC TGC ACA AGC CAT C -3’ 
L_F                                        5’-GAT GGC TTG TGC AGA AGA TTG G -3’ 
s_LF                                      5’-GCT GGA TTT CCT GAA GAG CGA -3’ 
s_LR                                     5’-AGT GAA ACA TCC AAA GTT GAT T -3’ 
F_F                                        5’-TCT GCT GCC GCC TAG TAG TTC -3’ 
F_R                                       5’-CCA ACC TGG TGA AAA CCT GTA A -3’ 
s_FF                                     5’-CTC CAT CTT TTA AGA AAT CCA G -3’ 
s_ FR                                    5’-TGA ACC TCC CGT ACA GGG CT -3’ 
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II.V Denaturing high-performance liquid chromatography 
(d-HPLC) 
 
 
 
 
D-HPLC WAVE (denaturing-high performance liquid chromatography) is one of the 
most frequently used methods for the diagnosis of DNA mutations. Highly sensitive 
and utilising recently  developed  methodology, d-HPLC is based on heteroduplex 
formation of PCR products amplified from both wild type and mutant alleles. Under 
optimised  semi-denaturing  conditions,  these  heteroduplexes  can  be  distinguished 
from homoduplexes. 
As with direct sequencing, to increase the sensitivity and specificity of ABL1 kinase 
domain  amplification, a nested-PCR approach methodology was utilised. The first 
round of amplification was carried out using 2µl of cDNA in a 50µl final reaction, 
using primers Fwd-BCR-P210 (positioned between exons e12 and e13 on BCR gene) 
and Rev-ABL-B (positioned on exon 10 on ABL gene) (Fig.2.2). Re-amplification of a 
2µl aliquot from first step PCR was then performed  using three internal primer pairs:  
Fwd-ABL-A/Rev-ABL-A,  Fwd-ABL-B/Rev-ABL-B  and  Fwd-ABL-C/Rev- ABL-C. 
As a result, the entire ABL kinase domain is divided into three  partially overlapping 
fragments: ABL-A (393 bp, spanning codons 206-335), ABL-B (482 bp, codons 262-
421), ABL-C (465 bp, codons 371-524) (fig.2.2). Primer sequences and their position 
on ABL are shown in Table 2E. 
This  strategy  produces  PCR  products  of  optimal  length  for  D-HPLC  Analysis 
(recommended length, 200-500 bp). Using WAVE 4500HT D-HPLC (Transgenomic 
Ltd.) melting curves were calculated as described to select optimal temperatures for the 
three ABL mRNA fragments. In order to allow the heteroduplexes to form, and 
depending on the intensity of the band obtained by gel electrophoresis, aliquots of 6- 
10µl of the PCR product, was incubated for 10 minutes at 96
o
C and then allowed to 
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cool for 10  minutes at room temperature.   The samples were then loaded onto the 
WAVE and run at the  following selected temperatures: ABL-A at 61.3, 62.3, and 
63.1
o
C; ABL-B at 60.3, 61.1, and 61.9
o
C; ABL-C at 60.2, 60.9 and 61.2
o
C. DNA was 
eluted from the column by a linear acetronitrile gradient in 0.1mM triethylamine acetate 
buffer (TEAA; Transgenomic) at a constant flow rate (1.5ml/min). Gradient was 
formed by mixing buffer A (0.1 mM TEAA) and buffer B (0.1mM TEAA, 25%  
acetonitrile). Eluted amplicons were detected by 260nm UV absorbance. A wild-type 
p210 BCR-ABL1 cDNA sample, derived from a BaF3 cell  line transfected with a 
BCR-ABL1 fusion construct, was also used as wild-type. 
The chromatogram from each tested patient was overlaid with the wild-type profile, 
and samples  with extra peak(s) in the elution profiles were scored as positive. To 
ensure that mutations present in >85% of BCR-ABL1 positive cells could not escape D-
HPLC detection, a mixture of all the  amplicons described as mutated by direct 
sequencing and wild-type transcripts was also run,  in  order to allow formation of 
heteroduplexes in the presence of a mutant homoduplex. 
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                                                                                          KINASE DOMAIN 
 
              1 1 12 13 14 a2 a3 a4 a5 a6 a7 . . . a10 a11 
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Fragment C 
                                                                                                             
                                                                                                               Fwd-ABL-C       Rev-ABL-C 
 
 
                                                                                                                
 
 
 
 
 
 
 
 
Fig.2.2. Position of amplified fragments on the BCR-ABL1 transcript. 
For all patients, the second round PCR was performed using three primers pair, in order to 
subdivide the entire ABL KD into three partially overlapping fragments (A, B, and C) of 
optimal recommended length of 200-500 bp for WAVE 4500HT D-HPLC analysis. 
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Table 2E: Sequence and position of primers used for the D-HPLC PCR of BCR-ABL1. 
 
 
 
 
 
Primer name 5’ to 3’ sequence Position 
 
 
 
Fwd-BCR p210     GAGCAGCAGAAGAAGTGTTTCAGA           BCR, exon 12 
 
Rev-ABL 
 
    CTTGGAGTGAGGCATCTCAG 
 
         ABL, exon 10 
 
Fwd-ABL-A 
 
    CATCATTCAACGGTGGCCGACGG 
 
          ABL, exon 4 
 
Rev-ABL-A 
 
     GTTGCACTCCCTCAGGTAGTC 
 
         ABL, exon 6 
 
Fwd-ABL-B 
 
   GAAGAAATACAGCCTGACGGGTG 
 
        ABL, exon 4 
 
Rev-ABL-B 
 
    CGTCGGACTTGATGGAGAA 
 
         ABL, exon 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II.VI Pyrosequencing 
 
 
 
When a BCR-ABL1 mutation was detected by direct sequencing in a patient for 
whom we had  at  least three consecutive cDNA samples, these were subjected to 
pyrosequencing in accordance with the manufacturer‘s instructions (Pyrosequencing 
AB,  Uppsala,  Sweden).  Pyrosequencing  is  a  real-time,  sequencing-by-synthesis 
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technique, catalysed by four kinetically titrated enzymes,  DNA polymerase, ATP 
sulfurylase, luciferase, and apyrase. It principally differs from direct  sequencing in 
the order the nucleotides are incorporated. Each nucleotide is dispensed and tested 
individually for its incorporation into a nascent DNA fragment. After each nucleotide 
incorporation, pyrophosphate (PPi) is released in a quantity equimolar to the amount 
of nucleotide incorporated. ATP sulfurylase quantitavely converts PPi to ATP in the 
presence  of  adenosine  5’  phosphosulphate.  ATP  is  then  used  by  luciferase  in 
converting luciferin into oxyluciferin, which generates visible light with an intensity 
that is proportional to the amount of ATP. The light generated is detected by a charge 
couple device (CCD) camera and  displayed as a peak in the software, where each 
peak  is  proportional  to  the  number  of  nucleotides  incorporated.  Unincorporated 
dNTPs  and  excess  of  ATP  are  continuously  degraded   by  apyrase.  After  the 
degradation is completed, the next dNTP is added in a new  pyrosequencing cycle, 
contributing to building up the complementary DNA strand. To  pyrosequence an 
unknown DNA sequence, a cyclic nucleotide dispensation order (NDO) is generally 
used. As a result of each cycle per nucleotide, one of the four dNTPs is incorporated 
into the DNA growing strand, whereas the other dNTPs will be degraded by apyrase 
(fig.2.3.). On the other hand, if the DNA sequence to be pyrosequenced is known, 
non-cyclic  NDOs  can  be  programmed  with  predictable  pyrograms.  Nucleotide 
sequence is determined from the order of  dNTPs dispensation and peak intensity 
using a pyrosequencing software. 
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Fig.2.3. Principle of pyrosequencing. As clarified in the procedure section at  
http://www.qiagen.com/products/pyromarkq24.aspx. 
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The BCR-ABL1 amplicon was used as a template for nested PCR using primers (with 
a 1µM concentration) that flanked the region containing the putative mutation. One 
of the 2 primers for each reaction was biotinylated. Sequence and position of some of 
the primers used for pyrosequencing reactions are shown in table 2A and fig.2.1. 
Each PCR product was tested in duplicate. In brief, a single-stranded cDNA was 
isolated   by   combination   of   alkali   denaturation   buffer   (NaOH)   and   mixing 
biotinylated PCR products with streptavidin-coated sepharose beads (GE Healthcare, 
Amersham, UK). The percentages of mutant and non-mutant were determined by the 
Allele Quantitation Algorithm using the PSQ
TM  
MA software (Pyrosequencing AB, 
Uppsala, Sweden). 
Purification of target complementary strand of PCR product was done as described 
briefly below: 
1. 20µl PCR product were transferred to a 24-well microtitre plate to which 70 µl 
Binding buffer had already been added. The plate was sealed with Micro Amp clear 
adhesive film (Applied Biosystem, USA). 
2. The microtitre plate was spun on the Monoshaker at maximum settings for 20 min. 
 
3. The adhesive film was disposed of and the microtitre plate was placed on to the 
template preparation platform for pyrosequencing. 
4. The vacuum pump connected to the hand held 24-pin grid was started. 
 
5. The grid was then transferred to the microtitre plate making sure that each pin 
went to the bottom of the well till fluid was completely sucked out. 
6. The grid was then transferred to the trough containing the 70% ethanol for 10-20 
seconds to eliminate the bead residues. 
7. The grid was then quickly transferred to the trough containing the denaturation 
buffer (NaOH) for about 5 seconds to denature the double stranded PCR product. 
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8. The grid was transferred into the trough containing the Wash Buffer (Biotage) and 
after the entire buffer went through the grid the pump was switched off. 
9. The  grid  was  transferred  to  the  24-well  pyrosequencing  plate  containing  the 
annealing buffer and primer mix (see appendix 5). The grid was shaken properly to 
release the beads from the tips into the respective wells. 
10. To anneal the sequencing primer to the single stranded template, the plate was 
heated at 80
o
C for 2 min using the pyrosequencing iron, followed by slow cooling to 
RT. 
11. The plate was placed in the slot of the pyrosequencing instrument. 
12. The cartridge was filled with the enzyme and substrate mix and the 4 dNTPs in 
the  respective  wells  as  per  instructions.  The  cartridge  was  then  loaded  into  the 
pyrosequencer head and the reaction started. 
13.  The  pyrosequencing  results  were  analysed  using  PyroMark  Q24  software 
 
(Biotage, Uppsala Sweden). 
 
 
 
 
The linearity of Q-SNP by pyrosequencing was tested by subjecting cDNA generated 
from  graded   mixes  of  Ba/F3  cell  lines  transfected  with  BCR-ABL1  cDNAs 
containing either the wild-type  ABL1 sequence (BaF3/BCR-ABL1) or the E255K 
mutation (BaF3/BCR-ABL1 E255K). The  mixes  ranged from 10 to 100% BCR- 
ABL1 E255K (Figure 1-3). To ensure reproducibility, the  cDNA synthesised from 
each  mix  was  tested  in  triplicate  by  Q-SNP.  A  similar  experiment  with  lower 
percentage  of  mutations  -including  1,  2  and  5%  mutation-  was  repeated  using 
BaF3/BCR-ABL T315I cells diluted against non-mutant BaF3/BCR-ABL1 cells. 
For both D-HPLC and pyrosequencing, in presence of uncertain cases the samples 
were run  together  with positive control from vector pMIG210 carrying wild-type 
BCR-ABL1 (kindly provided by Dr S.Wagner, Imperial College). 
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II.VII. Transformation into competent bacteria 
 
 
 
 
The pMIG210 vector contains the cDNA encoding the 210KDa form of BCR-ABL1, 
and the gene  for the enhanced green fluorescent protein (EGFP), preceded by an 
internal ribosome entry site (IRES) and an ampicillin resistance cassette. 
For propagation of pMIG210 plasmid, an aliquot of 10pg to 100ng of the vector was 
transfected into chemically competent cells (One Shot TOP10 vector kit, Invitrogen, 
CA, USA). The cells were then left on ice for 30min, subjected to heat shock at 
42°C for 30 seconds and transferred back on ice for  1 min. SOC medium for 
bacterial growth (250µl) was then added to the cells, which were  incubated  at 
37°C for 1h. After that, the content of each vial was plated on a selective agar 
plate  (LB agar containing 100µg/ml ampicillin) and the plates were incubated 
overnight at 37°C to allow colony formation. 6 colonies were picked the next day, 
using the tip of a P200 Gilson pipette, and transferred each to a 15ml Falcon 
containing 5ml of L-Broth and 100µg/ml ampicillin. Liquid colonies were allowed to 
grow for 18 hours followed by plasmid DNA  extraction using the Qiagen Miniprep 
Plasmid Isolation kit (Qiagen, Hilden, Germany). 
 
 
 
 
 
 
 
 
II.VIII. Statistical Analysis 
 
 
 
 
The graphs have been generated by using SPSS v19 software (SPSS, Inc., Chicago, 
IL). All statistical analyses were two-sided. 
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      III. Results 
 
 
 
 
 
 
 
III.I Estimation of the sensitivity of different conventional 
methods for BCR-ABL1 kinase domain mutation analysis 
 
 
 
 
Six serial dilutions were created using wild-type cDNA and E255K BCR-ABL1 
cDNA, both extracted from BCR-ABL1 transfected BaF3 cell lines. Mutant cDNA 
was diluted in WT cDNA to create the following serial dilutions: 40%, 20%, 10%, 
5% and 1%. Dilutions were amplified for kinase domain of ABL1 in a nested PCR 
and  the  final  product  was  tested  for  detection  of  mutation  E255K  by  direct 
sequencing, pyrosequencing and d-HLPC. 
Direct sequencing. DS was able to detect mutation E255K up to the 20% dilution, 
while could not  pick up any abnormality in 10%, 5% or 1% dilution samples. No 
other mutations were detected in either of these dilutions, confirming the absence of 
contamination.  The  level  of  sensitivity  of  direct  sequencing  has  been  therefore 
considered to be above 20%, in accordance with previous studies from Baccarani
87
 
and Ernst.
88 
 
Pyrosequencing. Pyrosequencing was able to detect the mutation up to 5% dilution, 
while could not pick up any abnormality in 1% dilution samples. Thus, the level of 
sensitivity for pyrosequencing  from this study has been described as equal to or 
above 5%, in accordance with previous studies from Baccarani and colleagues.
87
 
Denaturing-High  Performance  Liquid  Chromatography.  In  order  to  assess  d-
HPLC sensitivity, in addition to the E255K-mutant dilutions, I investigated another 5 
serial dilutions  of T315I-mutant cDNAs, already mixed and kindly provided by 
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Junia Melo (Institute of Medical and Veterinary Science, Adelaide). First and 
second-step PCRs were prepared and run by myself, as was the loading of the PCR 
products onto the d-HPLC apparatus. E255K mutation is located on  exon 4 of 
ABL, at 109 nucleotide position of the amplicon and it is expected to appear on 
fragment A. However, this mutation did not show a consistent signal on the d-HPLC 
chromatogram for any of the dilutions and it was not therefore possible to interpret 
the results. Further work is needed to  optimise the assay to enable reliable 
detection. 
The results for the T315I-mutant dilutions were different. This mutation is located on 
exon 6 of  ABL, at 290 nucleotide position of the amplicon. Therefore, fragments 
expected to show mutant pattern were A and B (as previously shown in table 2C). 
D- HPLC was able to detect mutation T315I up to 1% dilution in all the fragments B, 
as show in fig.3.3. Conversely, T315I was not identified in fragment A and this is 
likely to be due to its location in proximity of the end of the fragment A.  
Therefore, d- HPLC from this study has been described as having a sensitivity 
around 1% for the E255K mutation in accordance with previous studies from 
Baccarani
87 
and Ernst
88
. 
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Fig 3.1: Results from serial dilution experiments to assess the sensitivity of the d-HPLC assay. 
PCR products amplified from wild-type ABL1 and 5 serial dilutions of T315I mutant were mixed as 
indicated and subjected to d-HPLC. Each of the 5 chromatograms represents d-HPLC profiles of 
fragment B for T315I mutation from 40%, 20%, 10%, 5% and 1% dilutions respectively, following 
graphs from top to bottom. First of the 2 peaks represents the mutant fragments, which in the 40% 
dilution is still visible as double peak; the second peak represents the wild-type fragment. The degree 
of difference varied from an obvious heteroduplex peak (40%) dilution to a homoduplex peak (1% 
dilution) depending on the amount of the mutant cDNA. 
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III.II Results of mutation analysis in patients treated with 
IM and 2G-TKIs 
 
 
 
 
 
III.II.A Patients’ clinical features 
 
 
 
 
This section includes the results from the study of the whole cohort of 269 patients 
treated with imatinib followed by second-generation TKIs, whose characteristics 
were presented in Chapter II. At the  start of treatment, 193 (72%) patients were in 
chronic phase, 61 (23%) in accelerated phase and 16 (6%) in blastic crisis. During 
treatment, 163 (84%) of the 193 CP patients remained in CP, while 29 (14%) 
progressed to advanced phase (accelerated phase and blastic crisis). Of the 61 
patients initially in AP, 30 (49%) went into CP and 6 (10%) progressed to BC. Of 
the 16 patients who started treatment in BC two (13%) went into AP and 4 (25%) 
into CP. 164 of the 269 (61%) patients achieved complete cytogenetic response 
(CCyR) during treatment with imatinib (n=85, 52%) or one of the three second-
generation TKIs (dasatinib: n=45, 27%; nilotinib: n=29, 17%; bosutinib: n=4, 
2%). All patients’ characteristics are shown in table of Appendix 6. 
 
 
 
 
 
 
 
 
III.II. B Acquisition and loss of mutations during treatment 
 
 
 
Results from mutation analysis by direct sequencing showed 63 mutated patients (out 
of the 269 total patients, 23%). Of these 63 patients 44 developed mutations during 
treatment with IM. Most of these patients  (48  out  of  63,  76%)  had  a  single  
mutation.  However,  eleven  patients developed 2 different  mutations, three 
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patients had 3 mutations and one patient harboured  4  different  mutations.  23  of  
the  154  (15%)  patients  who received both  imatinib and second-generation 
tyrosine-kinase inhibitors developed mutations on imatinib; of these, two (9%) 
developed new mutations during treatment with 2G-TKIs with loss of the mutation 
present at baseline, six (26%) maintained the same mutation from imatinib to end of 
therapy, seven (30%) lost their mutation and seven (30%) acquired new mutations 
in addition to the mutation occurred  during imatinib. Five of the 269 (2%) patients 
had more than one mutation during treatment with   imatinib,   with   the   following   
genotypes:   Y253H/M351T,   E459K/T315I, L384M/V338F, M351T/H396R, 
G250E/T315I. 
 
 
 
 
 
III.II.C Frequency and relative distribution of mutations 
 
 
 
Overall, out of the 269 patients, mutational analysis by direct sequencing detected 63 
(23%) patients harbouring 77 mutations at 23 different amino acids, with a total of  
30  different  mutations.  Eleven  (18%)  of  the  63  mutated  patients  harboured 
multiple mutations. The residues affected by amino acid substitutions spanned the 
whole BCR-ABL1 kinase domain; in detail, the group of AA substitutions occurring 
with the highest frequency were within the gatekeeper domain, with 4  different 
amino acidic substitutions detected (V299L, T315I, T315A, F317L) occurring in 23 
(37%) patients. A second group of frequently detected mutations was found to fall 
within the P-loop  region, with 6 different substitutions (L248V, G250E, Q252H, 
Y253H, E255K, E255V) all together affecting 21 (33%) of the mutated patients. 
The  catalytic  domain  represents  another  region  of  BCR-ABL1  KD  frequently 
mutated in CML, and was found to be involved in 12 (19%) cases with 5 distinct
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nucleotide  changes  (M351T,  E355G,  F359C,  F359I,  F359V).  Four  different 
mutations (L384M, L387M, H396R) were clustered within the activation loop, with 
4 cases (6%). Finally, mutations falling within the C-loop (E450K, E450V, E453K, 
E453V,  E459K,  E462K, F486S) were detected in 7 (11%) patients. Some other 
detected mutations (M244V – which used to be considered as part of the P-Loop - 
D276G, V338F, S417F) do not belong to any of the 5 recognised functional regions 
mentioned above. 
T315I and G250E were the two most common single mutations with the gatekeeper 
domain  being  the  most  frequently  affected  in  BCR-ABL1  KD.  Frequency  of 
detected KD is shown in fig 3.2. 
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Fig.3.2. Distribution and relative frequency of KD mutations found in my study. Incidence of mutations 
within the kinase domain (x-axis) by absolute number of patients (y-axis). 
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III.II.D Emergence of KD mutations and their frequency according to 
disease phase 
 
 
 
 
Mutations were found in: 32 out of 198 (16%) CP patients; 24 of 87 (28%) AP 
patients;  6  out   of  17  (35%)  BC  patients  (table  3B).  Difference  in  mutation 
occurrence rate was therefore  not  substantial for patients in accelerated phase or 
blastic crisis.  However, when examination of the position and relative frequency of 
mutations by disease phase was conducted, we observed highly resistant gatekeeper 
mutations  T315I  and  P-loop  mutations  showing  a  preferential  trend  toward  the 
advanced stages of disease (fig. 3.3). 
 
 
 
 
 
 
 
 
III.II. E Mutations occurrence and disease progression 
 
 
 
 
 
 
In our cohort most of the patients remained in CP (61%). However, most of the patients 
who progressed from chronic to advanced phase harboured KD mutations; of the 24 
patients who progressed from CP to AP, 16 (67%) were mutation-positive. 3 out of 5 
(60%) of the patients who progressed from CP to BC carried  a  mutation.  Some  
patients  developed  more   than  one  mutation  before progressing to advanced phase, 
with a total number of 19 mutations.  Five  of these mutations occurred in more than 
one patient during their disease progression: T315I and G250E both occurred in 3 
different patients; M351T, E255K and F317L were detected each in 2 patients. When 
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the 19 KD mutations involved in the progression to advanced  phase were categorised 
on the grounds of their AA position, it was found that 11 out of the 19  (85%) were 
gatekeeper and P-loop KD mutations, characterised  by  high  levels  of  resistance  
(i.e.  G250E,  T315I,  E255K,  F317L, Y253H). Patients harbouring these mutations 
showed a substantially worse outcome than the patients carrying mutations with low or 
intermediate levels  of  resistance during disease progression. 
 
 
 
 
 
 
 
 
 
Table 3A. Mutated patients and their occurrence within different stages of the disease 
 
 
 
  
         Total pts MUT 
         n n, (%) 
 
CP 
CP --> AP  
CP --> BC 
 
164 
 
        20 (12) 
 
24 
 
        16 (67) 
 
5 
 
3 (60) 
 
AP 
AP--> CP  
AP --> BC 
 
25 
 
6 (24) 
 
30 
 
        10 (33) 
 
6 
 
2 (33) 
 
BC 
BC --> AP  
BC --> CP 
 
10 
 
2 (20) 
 
2 
 
       2 (100) 
 
4 
 
2 (50) 
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Fig.3.3. Distribution and relative frequency of KD mutations according to disease phase. CP, chronic  
phase;  AP,  accelerated  phase;  BC,  blast  crisis.  Gatekeeper  mutation  region  T315I  and 
mutations part of the P-loop domain (AA248 – 255) occurred in advanced phases at higher frequency. 
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III.II. F Development of KD mutations and loss of CCyR 
 
 
 
In 20 (12%) of the 164 patients who achieved CCyR, mutational analysis showed the 
emergence of  BCR-ABL1 mutations. Out of these,  five patients (25%) had one 
mutation detected before they achieved CCyR (H396R, E276G, Q252H and 
V299L, with the latter being harboured by two patients); i n  the same patients  
despite the above listed mutations were still detectable, BCR-ABL1 levels continued 
to decrease and CCyR  was  maintained  during treatment. CCyR was achieved 
during treatment with dasatinib (2 patients) and nilotinib (3 patients).  
In 15 patients mutations (T315I   n=2, N231S, F359I, L384M/V338F, S417F, 
E453V, M351T/H396R, Y253H, V299L, F359V, G250E, F359V, E450V and 
F317L) were detected while in CCyR. Of these, eleven patients (representing 55% 
out of the total patients  who  achieved  CCyR)  lost  response,  with  one  
individual  progressing eventually to advanced phase. Patients with mutation 
showed to be more likely to experience loss of response. Eighteen (10%) of the 164 
patients who achieved CCyR lost their response during  follow up without showing 
presence of mutation (data shown in table 3B). 
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Table 3B: Correlation between development of KD mutations, disease phase and achievement of 
response. 
 
 
 
 
GROUP no. of pts 
Achievement of CCyR 
Loss of response                         
                                                                                                                        n. (%) 
ALL PATIENTS 269 164 (61) 29 (18) 
BCR-ABL1 MUTATION 
Yes 63 20 (12) 11 (55) 
No 206 144 (88) 18 (12) 
DISEASE PHASE 
CP 198 143 (72) 24 (17) 
AP 87 20 (23) 4 (20) 
BC 17 1 (6) 1 (50) 
 
MUTATIONS IN CP 
Mutation 32 (16) 20 (63) 9 (35) 
No mutation 166 (84) 123 (74) 15 (12) 
 
MUTATIONS IN AP 
Mutation 24 (28) 4 (17) 1 (28) 
No mutation 63 (72) 17 (27) 3 (18) 
 
MUTATIONS IN BC 
Mutation 6 (35) 1 (16) 1 (100) 
No mutation 11 (65) 1 (9) 0 (0) 
 
Abbreviations: CCyR indicates complete cytogenetic response. 
“Loss of response” column represents patients who lost response after achievement of CCyR and its percentages 
are referred to “Achievement of CCyR” column. 
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III.II.G.  Assessment  of  mutation  emergence  “specificity” 
during dasatinib and nilotinib treatment 
 
 
 
 
As already reported in this study, results from mutation analysis by direct sequencing 
found 30 different mutations occurring in patients during treatment with imatinib and 
second generation TKIs.  Some of these AA substitutions appeared to have a high 
frequency  of  occurrence,  such  as  T315I  (n=14),  G250E  (n=10),  M244V  (n=5), 
F317L (n=5) and Y253H.  Emergence of T315I was detected during IM, dasatinib, 
nilotinib and bosutinib; G250 and M244V both developed during IM, dasatinib and 
nilotinib. Conversely, Y253H was only detected on IM (n=1) and nilotinib (n=3); 
F317L only occurred on dasatinib (n=5) (fig.3.4). 
Soverini and colleagues
89  
in a recent study on acute lymphoblastic leaukaemia 
reported that treatment with second-line TKI dasatinib  (following resistance to  
imatinib) may select  TKI-specific  BCR-ABL1 mutants. 
Because direct sequencing sensitivity is over 20%, there was the possibility that in 
my samples  mutations F317L and Y253H had in reality appeared during previous 
treatment with imatinib, when their levels were not sufficient to be detected by direct 
sequencing. Thus in order to assess whether  Soverini’s theory could be applied to 
my patients’ cohort, samples from the five patients were analysed by pyrosequencing 
to  assess  F317L  emergence  only  after  introduction  of  dasatinib.  Furthermore, 
following the same procedure, samples from the three patients bearing mutation 
Y253H were also tested to assess development of the mutation only following start 
of treatment with nilotinib. 
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In order to track back the appearance of these two mutations and assess their actual 
point in time of occurrence, analysis by pyrosequencing was carried out on at least 4 
cDNAs of each of the 5 patients with F317L and 3 patients with Y253H. 
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Fig.3.4  Distribution and relative frequency of KD mutations according to treatment with TKIs. 
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Dasatinib and F317L emergence study 
 
 
 
 
At the time of F317L mutation detection, out of the five patients 3 were in 
chronic phase and two in accelerated. Three patients had concomitant mutations 
in addition to F317L (with M351T and H396R, M244V, M351T and F311L; the 
latter eventually also acquired G250E  and  T315I). After a median time of 6 
months (range 5-8) from F317L detection, two of the CP patients progressed to 
accelerated  phase,  and  one  of  the  AP  patients  went  into  BC   (patients’ 
characteristics are reported in table 3C). Results from pyrosequencing confirmed 
for  all  the five patients that F317L mutation had emerged only after dasatinib 
was administered, with the median time from start of dasatinib to detection of 
the F317L mutations being 6 months (range 2-9 months). 
Reported in Fig.3.4. are the monitored kinetics of the mutations in relation to 
treatment variation over periods ranging from 20 to 40 months respectively for 2 
of the patients who developed F317L.  
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Fig 3.5. Results  from pyrosequencing analysis show emergence of F317L BCR-ABL1 
kinase domain mutation following dasatinib therapy in two representative patients. 
The kinetics of the BCR-ABL1 transcripts measured by RQ-PCR is represented by the bold 
black line in all 4 panels (expressed as a ratio to the ABL control transcripts x 100%). The 
coloured lines represent the proportions of the mutant subclones measured at different time 
points. Months under treatment represent the time from imatinib start. 
 
PATIENT A: A 64-year-old male was started on 400mg daily IM. After 9 months of 
treatment mutation G250E was identified. Due to lack of response treatment was changed to 
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dasatinib, and after 4 months reduction in both G250E mutant clone and BCR-ABL1 ratio 
could be seen. However, mutant F317L levels started to increase and after 10 months from 
the start of  dasatinib both BCR-ABL1 transcript levels and F317L clone increased, while 
G250E  continued  to  decrease.  At  that  time  patients  was receiving  90mg  of  dasatinib  
daily. Standard  dosage  of  dasatinib  (100mg) resumed  1  week  after  and  BCR-ABL1  
levels  drastically decreased, together with G250E levels, while F317L remained stable. 
This suggests the 2 mutations,  evolving discordantly,   belonged  to   2  different  subclones. 
  
PATIENT D: A 60-year-old male who relapsed after BMT, underwent treatment with IM 
for 3 months: BCR-ABL1 ratio decreased, but 2 mutations  were detected: M351T and 
G250E. One month later, treatment was replaced with dasatinib,  which after 2 months 
caused a decrease in BCR-ABL1 ratio. The 2 mutant M351T and G250E levels increased, 
and an additional mutation, F317L appeared.  After over 2 years of treatment with dasatinib, 
nilotinib was introduced and BCR-ABL1 levels in the first instance decreased, only to then 
increase  to  their  previous  %  level.  Mutation  G250E  rapidly  increased,  while  F317L 
drastically  decreased.  M351T  mutant  levels  became  undetectable.  As  a similar  trend  
was observed for F317L and M351T mutants during the final disease phase, the possibility 
that the 2 mutations belong to the same subclone cannot be excluded. 
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                      Table 3C. Characteristics of the five patients showing emergence of F317L mutation on dasatinib. 
 
 
 
 
 
DISEASE 
PHASE ON 
IMATINIB 
MUTATIONS 
ON 
IMATINIB  
DISEASE 
PHASE 
START OF 
DASATINIB 
TIME ON 
DASATINIB 
BEFORE 
F317L 
(months) 
DISEASE 
PHASE 
AFTER 
F317L 
DETECTION 
DISEASE 
PHASE ON 
NILOTINB 
MUTATIONS 
ON 
NILOTNIB 
TYPE OF 
RESPONSE 
AFTER 
F317L 
Patient A CP G250E CP 4 CP CP / NR 
Patient B CP 
M351T;  
H396R 
CP 6 CP CP / NR 
Patient C CP M244V CP 3 AP CP / LOR 
Patient D CP M351T CP 9 AP CP 
G250E;   
T315I 
NR 
Patient E CP / AP 2 AP CP / NR 
 
 
 
                     CP, chronic phase. AP, accelerated phase. NR, no response. LOR, loss of response 
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Nilotinib and Y253H emergence study 
 
 
 
 
 
 
 
Of the 63 mutation-positive patients, four were found by direct sequencing to 
harbour  mutation  Y253H.  Since  one  patient  showed  such  mutation  during 
imatinib treatment, it was excluded from the study. Samples of the three other three 
patients for which T253H was detected by direct sequencing from nilotinib start were 
further analysed by pyrosequencing. At start with nilotinib, two of the three patients 
were in chronic phase and one in accelerated phase. One patient had concomitant 
mutations in addition to Y253H (E459K and T315I). None of the three patients 
showed a progression of disease phase. 
Results   from    pyrosequencing   confirmed   emergence  of Y253H from 
administration of nilotinib only in one patient. In the other two patients the 
mutation was picked up during treatment with imatinib after a median time of 9 
months from its start. For the only patient in which pyrosequencing confirmed 
Y253H as arisen after start of  therapy with nilotinib, mutation kinetics were 
monitored in relation to treatment variation over  a period of 15 to 56 months 
(median 35.5 months) (Fig.3.6). 
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PATIENT E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.6. Emergence of Y253H BCR-ABL1 kinase domain mutation following nilotinib 
therapy in one patient. The kinetics of the BCR-ABL1 transcripts measured by RQ-PCR are 
represented by the bold black line in all 4 panels (expressed as a percentage ratio over the 
ABL1 control). The proportions of the mutant subclones measured at different time points 
are represented by the coloured lines. 
Under  imatinib  treatment  the  patient  developed resistance  and  was  therefore moved  to 
second-line treatment nilotinib. BCR-ABL1 ratio dropped rapidly and with the exception of a 
short increase in its levels, the patient achieved a reduction greater than 1 log. Emergence of 
Y253H  mutation was identified at the third month after introduction of nilotinib and its 
levels continued  to increase during the whole treatment duration. Emergence of E255K 
mutation was also detected, but it became undetectable after a two-month period. 
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III.III. Mutation analysis of kinase domain SFKs 
 
 
 
 
 
 
 
Previous analysis from this work characterised 63 (23%) of the initial cohort of 
269 patients as BCR-ABL1 mutation positive. Out of the 206 patients not 
harbouring a BCR-ABL1 mutation, 24 had been selected on the basis of treatment 
with either dual SFK/BCR-ABL1 inhibitors dasatinib or bostinib and when 
resistance to treatment was observed.  
Patients’ characteristics of the latter subset are reported in table 3D. Kinase 
domains of Hck, Lyn and Fyn were amplified for each of the patients and subjected 
to direct sequencing for screening of SFK KDs.  
None of the 24 patients showed presence of such mutations. More recently, however, 
it was pointed out that, at the time of the SFK analysis, 6 patients out of the 24 
originally selected presented a BCR-ABL1/ABL1 percent ratio less than 49%, 
leading to possible false-negative results and therefore calling the analysis invalid for 
this subset of patients presenting background normal cells as the predominant 
population. 
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Table 3D. Patients’ characteristics for the subgroup of 24 patients selected for the dual SFK/BCR-ABL1 study. The only patient treated with bosutinib 
was in AP. Of the 23 patients on dasatinib, 10 were in CP, 7 in AP and 6 BC. None of them was a responder or harboured a BCR-ABL1 mutation. At the time 
of analysis 6 patients showed a BCR-ABL1/ABL1 percent ratio inferior to 50%, with the remaining 18 patients showing a BCR-ABL1/ABL1 percent ratio 
greater than 50%. The analysis has been therefore called invalid for this sublet of 6 patients. 
 
 
 
  Pts, n Age, yrs Sex Disease phase on dasa/bosu Previous T BCR-ABL1/ABL1, % 
      F M CP AP BC   10 - 49 50 - 100 
Tot pts, n 24 57 13 11 10 8 6 2 6 18 
Dasa 23 57 (31-82) 12 11 10 7 6 2 6 17 
Bosu 1 80 1 0 0 1 0 0 0 1 
 
   CP. Chronic phase. AP, accelerated phase. BC, blastic crisis.        
   T, transplant. 
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IV.Discussion 
 
 
 
 
 
The aim of this study was to conduct a systematic evaluation of the appearance, trend 
and  contribution to clinical resistance, of the various BCR-ABL1 mutations arising  after  
treatment  with  imatinib  and  the  second-generation  tyrosine  kinase inhibitors dasatinib, 
nilotinib and bosutinib. 
 
The introduction  of  selective tyrosine  inhibitors  for  the  treatment  of  CML  has 
revolutionised patient outcome and management of this disease. Imatinib is now the 
treatment of choice for  virtually all newly diagnosed patients. Good responses, in terms  
of  symptom  control  and  haematological  parameters,  are  usually  obtained. However, 
failure to eradicate completely malignant cells (primary resistance) or the difficulty  in  
maintaining  a  stable  response  to   treatment  (acquired  resistance), characterising a 
subset of patients, has led to an intensive search for the mechanisms responsible for 
resistance development and subsequent treatments through which this refractoriness  can  be  
overcome.  Resistance  has  been  associated  with  various mechanisms,  such  as  BCR-
ABL1  amplification,  low  TKI bioavailability  and  the acquisition of additional  
chromosomal abnormalities, but in the vast majority of patients, the decreased response 
to treatment is due to point mutations in the tyrosine kinase domain of BCR-ABL1.
50; 90 
In this study I have screened a large series of CML patients who had been treated at or 
referred to the Hammersmith Hospital and had shown resistance to IM or second-
generation  tyrosine  kinase  inhibitors.  Patients  that  were  intolerant  to  or  failed 
imatinib  treatment  became candidates  for second-line generation  tyrosine kinase 
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inhibitors,  such  as  dasatinib,  nilotinib,  and  bosutinib.  By  screening  BCR-ABL1 kinase  
domain  for  the  presence  of  mutations  we  detected  69  (23%)  patients harbouring a 
total of over 20 codons hit by  mutations. Stratifying the mutation appearance by 
disease phase I did not observed a  distinctive  difference in the frequency of mutation 
emergence in patients in chronic and advanced-stage disease. However, despite the high 
number of these mutations and the  consequently low relative frequencies of each single 
AA substitution, I observed that  gatekeeper mutation T315I and the majority of P-loop 
domain mutations were more recurrent in the advanced stages of CML. We also observe a 
recurrent association between the emergence of these mutations and the progression of 
the patient to more advanced disease phases. Predictably, patients harbouring T315I 
experienced resistance to all changes in TKI treatment, as previously reported by others.
81  
The reason for this mutation’s  pan-resistance is  that  the ‘gatekeeper’ threonine 315  
forms  a crucial hydrogen bond with all three TKIs, and the subsequent substitution with 
a bulkier and more hydrophobic isoleucine abolishes this bond formation, determining a 
steric clash that prevents the inhibitory action of the imatinib and other TKIs. The P-loop is 
a  highly  conserved  glycine-rich  region  occupying  residues  248-256  of  ABL1, 
responsible  for  ATP  phosphate  binding.
91   
Of  note,  the  findings  of  this  study 
paralleled  the  work  carried  out  in  other  centres  by different  investigators,
92,80,78 
especially the incidence of certain gatekeeper and P-loop mutations  prevalently in 
advanced phases, conferring a faster disease progression and refractoriness to second line 
treatment.  
 
Second-generation  tyrosine  kinase  inhibitors  nilotinib  and  dasatinib  are  active against 
most of imatinib-resistant mutations, but some confer clinical resistance to nilotinib (i.e. 
Y253H, E255K)
93
, to dasatinib (i.e. F317, V299L)
94,95 
or both (like the pan-
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resistantT315I).
95   
Detection  of these mutations  at  imatinib  failure  may help selection  
of  the  most  appropriate  alternative  treatment.  Thus,  mutation  analysis should be 
always necessary before start of treatment and changing to other tyrosine kinase 
inhibitors.
18  
Conventional direct sequencing is the golden standard for kinase domain 
mutation screening, 
96 
but it has a detection limit around  20%, with the risk of  failing  
detection  of  resistant  clones  present  below  this  level.  We  therefore assessed   
sensitivity   and   specificity   of   newer   available   techniques,   such   as pyrosequencing 
and d-HPLC and compared them with direct sequencing.  Results from this study showed 
that, despite being endowed with higher sensitivity and being suitable  for a large-scale 
screening, D-HPLC still presents discordant results with those from direct sequencing. 
This tendency for false positive results was reported in my case for nearly 30% of the 
samples, rendering the setting conditions unreliable for analysis of diagnostic specimens. 
This  would suggest that direct sequencing remains the method of choice at present for the 
detection of TKD mutations. Further study aiming to improve detection specificity and 
reliability of D-HPLC assay and will  be  resumed  in  the  nearest  future.  Through  
serial  dilution  experiments pyrosequencing proved to be a considerably sensitive 
methodology (higher than 5%) for detecting and measuring mutation levels. In the four 
representative patient cases, with a total average of 11 samples initially screened by direct 
sequencing followed by pyrosequencing, sensitivity of conventional sequencing was 
confirmed being of only 20%. In patients with a known or suspected mutation 
h is tory, even when classified as wild-type by direct sequencing, it was possible to detect 
up to 5% level of mutation.  On  this  basis,  pyrosequencing  allows  to  “track  back”  a  
mutation emergence,   resulting  in  the  construction  of  patients’  kinetics  and  
providing information concerning mutational patterns. The application of pyrosequencing 
can therefore allow for an early detection  of  mutations that confer resistance and this 
 102 
 
study at present suggests that this methodology should be applied to all patients in whom 
a mutation has been detected by conventional sequencing. Samples prior to and following 
the point at which mutation was detected should be tested. Because pyrosequencing 
shows a greater sensitivity than direct sequencing, this would allow for therapy 
interventions to switch to different and more effective treatment when the level of mutations 
shows a rise in repeated samples. 
 
In this project we additionally investigated the recurrent emergence of mutation 
 
F317L in patients on dasatinib, as previously reported by Soverini and colleagues.
94
 
Direct sequencing identified F317L in five cases during treatment with dasatinib; 
pyrosequencing confirmed F317L emergence being subsequent to the introduction of 
dasatinib.  In our patients the dominance of the mutant clone seemed to be the result of a 
selective effect exerted by dasatinib rather than of a proliferative advantage over the non-
mutant BCR-ABL1 clone. We followed the kinetics of 2 of the five patients reporting  
F317L  emergence  after  introduction  of  dasatinib  post  treatment  with imatinib. By 
pyrosequencing it was possible to quantify F317L levels, which had increased  during 
dasatinib administration. A fall in the level of the mutation was observed in both patients 
when dasatinib treatment was withdrawn to be replaced by nilotinib.  However,  in  both  
the   patients  the  reduction  in  F317L  level  was accompanied by an increase in the 
level of a clone carrying G250E mutation, which eventually dominated the leukaemic 
population. To date there are no data about the proliferative activity of G250E but being 
part of the P-loop, whose mutations Y253F and  E255K  have  been  reported  by  Griswold  
and  colleagues  as  having  greater transforming potential over non-mutant BCR-ABL1 
positive BaF3 cells,
97 
it can be hypothesised that G250E might also have higher 
proliferative potential and it did not dominate on dasatinib therapy because  F317L had a 
higher level of resistance to dasatinib. As soon as the selective pressure from the kinase 
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inhibitor was removed, the cells carrying G250E started to proliferate and became the  
dominant clone. It also proposes that G250E has proliferative advantage over the non-
mutant  BCR- ABL1 clone although this has not experimental confirmation yet. With 
dasatinib suspension  M351T  mutation  levels  also  fell  and  became  undetectable.  
Having M351T been described by Griswold et al.
97 
to have a reduced transforming 
potential than BCR-ABL1 wild-type, it additionally supports the theory that once the 
selective pressure exerted by the treatment is removed, mutations that had developed 
during its administration will either further develop or  disappear in correlation to their 
proliferative  advantage.  This  theory  stresses  the  need  for  early  detection  of  an 
emerging  resistant  clone  in  order  to  draw  a  more  stringent  follow-up  schedule 
allowing therapeutic choices to be made in a condition of low tumour load. 
 
Mutations within BCR-ABL1 kinase domain, however, account for many but not all cases 
of resistance. More concerning are a growing number of imatinib and second- generation 
TKI-resistant  CML patients who do not exhibit mutations in the Abl kinase domain but 
instead show a correlation with overexpression of SFKs, which are not direct targets for 
imatinib action.  Endowed with a dual target of action, SFK/BCR-ABL1 inhibitors have 
been shown effective in overcoming resistance due to Src family kinase overexpression. 
Yet, some patients of my cohort who were not harbouring BCR-ABL1 mutations did not 
respond to such treatment. 
 
 
The final aim of my thesis has been focused therefore on the investigation of the 
existence of point mutations within the kinase domain of the three member proteins of 
SFKs, namely Hck, Lyn and Fyn, as a potential factor contributing to treatment 
resistance. The study was carried out over a subset of patients that were resistant to 
SFK/BCR-ABL1 inhibitors dasatinib and bosutinib and  were  not presenting BCR- ABL1 
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mutations. To the best of our knowledge, ours was the first study to assess the presence of 
point mutations within the tyrosine kinase domain of Fyn and Hck in 
CML  BCR-ABL1  patients.  Wu  and  colleagues
98   
investigated  the  presence  of 
 
mutations in KD Hck on a relatively small (n=12) subset of CML resistant patients and 
could not identify any mutations. Although our field of study was larger (n=24) and each 
patient was  screened  for the presence of mutations in 3 distinct SFK members,  we 
were not  able to  detect  any mutation.  With  these results  we feel therefore the right to 
speculate that the emergence of mutations within the KD of the SFKs Hck,  Fyn and  Lyn 
might be a highly unlikely (if not  completely absent) mechanism of resistance exerted 
by CML and that further investigation should  be continued taking these findings into 
account. 
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Future Work 
 
 
 
 
 
 
 
The results  reported  in  my  thesis  raise  some  new  issues  which  could  well  be 
addressed in future work. 
 
Further assessment and analysis of the application of d-HPLC for mutation analysis in 
CML could  be carried out. Validation of this methodology can be pursued by following 
protocols already  assessed in previous studies and adapted within our laboratory, on 
samples characterised as mutation-positive by pyrosequencing, which is of a greater 
sensitivity than direct sequencing. 
 
With the first part of this project focused on the clinical significance of BCR-ABL1 kinase 
domain mutations and the problem of resistance, and the last one dedicated to the 
investigation of a possible  cause of this resistance, further investigation can continue by 
screening for BCR-ABL1 mutations and possible genomic aberrations at diagnosis,  in  
order  to  limit  the  expansion  of  potential  mutant  subclones  and 
formulate a “more-tailored” and effective therapeutic strategy. 
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Appendix 
 
 
 
 
 
 
 
 
 
 
Appendix 1. Reagents used for cDNA synthesis 
 
 
 
 
 
 
 
5mg/ml random hexamer primers: Reconstitute 50U pdN6 (Pharmacia) with 539µl 
of sterile water. Then add 21µl 0.5mol/L KCl. 
 
5X RT Buffer (usually supplied) with M-MLV reverse transcriptase (RT): 
0.25mol/L Tris-HCl, pH 8.3, 0.375mmol/l KCl, 15mmol/l MgCl2. 
 
25 mM dNTP stock: Mix an equal volume of ultrapure 100mmol/L dATP, dCTP, dGTP 
and dTTP 
 
0.1M dithiothreitol (DTT) usually supplied with M-MLV RT. 
 
 
cDNA mix: to 428µl of 5X RT-buffer add the following, 21.5µl of DTT, 85.5µl of 25 
mmol/l dNTPs, 45µl of 5mg/ml random hexamers and make up to 1000µl with sterile water. 
 
 
 
 
 
Appendix 2. Nested PCR 
 
 
 
 
 
 
The first step: to amplify across the BCR-ABL1 
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First-round PCR mix without Taq polymerase 
 
 
 
• Total volume- 10ml 
 
 
• 10Xbuffer (–MgCl2): 1ml 
 
 
• dNTP: 0.25mM 
 
 
• MgCl2: 1.8mM 
 
 
• Primer (Forward) B2A: 600nM 
 
 
• Primer (Reverse) JamR: 600nM 
 
 
• Water: add to total volume of 10ml 
 
 
 
 
 
 
Make aliquots of 200µl and store at -70’C. 
 
 
 
 
 
 
First-round PCR to amplify BCR-ABL1 transcript: 
 
 
• Add 1ml of Taq polymerase (5unit/µl) to 200µl of the PCR mix. 
 
 
• For each reaction, take 20µl of PCR mix; add 5µl of cDNA. 
 
 
• Run tubes in the PCR machine under Nick 60 program (Appendix 4) 
 
 
• Store PCR products at 4’C till the second-round PCR is run. 
 
 
 
 
 
 
The second step: to amplify the ABL1 kinase domain from the first round PCR products 
in order to exclude normal ABL1-kinase. 
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Second round PCR mix to amplify the ABL1- kinase domain 
• Total volume: 10ml 
 
 
• 10X buffer (-MgCl2): 1ml 
 
 
• dNTPs: 0.25mM 
 
 
• MgCl2: 1.8mM 
 
 
• Primer (Forward) NTPB+: 600nM 
 
 
• Primer (Reverse) NTPE-: 600nM 
 
 
• Water: add to total volume of 10ml 
 
 
• Make aliquots of 500µl and store at -70oC. 
 
 
 
 
 
 
Second round PCR to amplify ABL1-kinase domain: 
 
 
• To 500µl of the PCR mix add 2µl Taq polymerase 
 
 
• For each reaction, take 50µl of the mix and add 1µl of the first step PCR product 
 
(amplified BCR-ABL transcript). 
 
 
• Run on Nick-60 protocol (same as first round PCR). 
 
 
• Store the PCR products at 4oC. 
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Appendix 3. PCR conditions for Hck, Fyn and Lyn 
 
 
 
 
 
 
Hck-KD PCR amplification 
 
 
PCR-mix without Taq polymerase 
 
 
• Total volume: 10ml 
 
 
• 10Xbuffer (–MgCl2): 1ml 
 
 
• dNTP: 0.25mM 
 
 
• MgCl2: 1.8mM 
 
 
• Primer (Forward) H_F: 400nM 
 
 
• Primer (Reverse) H_R: 400nM 
 
 
• Water: add to total volume of 10ml 
 
 
 
 
 
 
Make aliquots of 200ml and store at -70
o
C. 
 
 
 
 
 
 
PCR to amplify Fyn_KD transcript: 
 
 
• Add 1µl of Taq polymerase (5unit/µl) to 200µl of the PCR mix. 
 
 
• For each reaction, take 20µl of PCR mix; add 5µl of cDNA. 
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• Run tubes in the PCR machine under Nick 60 program (Appendix 4). 
 
 
• Store the PCR products at 4oC. 
 
 
 
 
 
 
 
Fyn-KD PCR amplification 
 
 
PCR-mix without Taq polymerase 
 
 
• Total volume: 10ml 
 
 
• 10Xbuffer (–MgCl2): 1ml 
 
 
• dNTP: 0.25mM 
 
 
• MgCl2: 1.8mM 
 
 
• Primer (Forward) F_F: 400nM 
 
 
• Primer (Reverse) F_R: 400nM 
 
 
• Water: add to total volume of 10ml 
 
 
 
 
 
 
Make aliquots of 200µl and store at -70
o
C. 
 
 
 
 
 
 
PCR to amplify Fyn_KD transcript: 
 
 
• Add 1µl of Taq polymerase (5unit/µl) to 200µl of the PCR mix. 
 
 
• For each reaction, take 20ml of PCR mix; add 5µl of cDNA. 
 
 
 130 
 
• Run tubes in the PCR machine under Nick 60 program (Appendix 4). 
 
 
• Store the PCR products at 4oC. 
 
 
 
 
 
 
 
 
 
 
Lyn-KD PCR amplification 
 
 
PCR-mix without Taq polymerase 
 
 
• Total volume: 10ml 
 
 
• 10Xbuffer (–MgCl2): 1ml 
 
 
• dNTP: 0.25mM 
 
 
• MgCl2: 1.8mM 
 
 
• Primer (Forward) L_F: 400nM 
 
 
• Primer (Reverse) L_R: 400nM 
 
 
• Water: add to total volume of 10ml 
 
 
 
 
 
 
Make aliquots of 200µl and store at -70
o
C. PCR to amplify Lyn_KD transcript: 
• Add 1µl of Taq polymerase (5unit/µl) to 200µl of the PCR mix. 
 
 
• For each reaction, take 20µl of PCR mix; add 5µl of cDNA. 
• Run tubes in the PCR machine under Nick 60 program (Appendix 4). 
 
 
• Store the PCR products at 4oC. 
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Appendix 4: Nick_60 program 
 
 
 
 
 
 
95
o
C 3 min 
 
 
94
o
C 40 sec 
 
 
61
o
C 40 sec 32 cycles 
 
 
72
o
C 1 min 
 
 
72
o
C 10 min 
 
 
4
o
C 
 
 
 
 
 
 
 
 
 
 
Appendix 5: Buffer and mixtures for pyrosequencing 
 
 
 
 
 
Binding mixture: (for each sample) 
 
 
• 38µl Binding Buffer (Qiagen) 
 
 
• 2µl Cepharose beads 
 
 
 
• 20µl water 
 
 
• 20µl PCR product 
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Annealing mixture: (for each sample) 
 
 
• 24.2µl Annealing Buffer 
 
 
• 0.8µl sequencing primer 10µ
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Appendix 6. Clinical characteristics of the cohort of 269 patients. 
 
 
 
 
 
Alphabetical letter of Treatment Group: to be referred to the above table. Mutation boxes have been coloured in green or yellow if the mutation was detected 
before or after achievement of CCyR respectively. Red-coloured mutations were detected before disease progression. 
 
Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 MUT 4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
1 44 M A             1 IM     
2 40 M A             1 IM     
3 90 F A             1 IM     
4 80 M A             1 IM     
5 47 F A             1 IM     
6 65 M A T           1 IM     
7 38 F A             1 IM     
8 57 M A             1 IM     
9 82 F A             1 IM     
10 47 M A             1 IM     
11 64 M A             1 IM     
12 32 F A T           1 IM     
13 68 M A             1 IM     
14 36 M A             1 IM     
15 54 F A             1 IM     
16 56 M A             1 IM     
   Before 
CCyR 
     During 
CCyR 
   Before 
Disease 
progression 
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Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 MUT 4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
17 61 M A             1 IM     
18 56 M A             1 IM     
19 56 M A             1 IM     
20 73 F A             1 IM     
21 40 M A             1 IM     
22 72 F A             1 IM     
23 58 F A             1 IM     
24 38 M A             1 IM     
25 38 F A             1 IM     
26 67 M A             1 IM     
27 55 M A T           1 IM     
28 46 M A             1 IM     
29 20 M A             1 IM     
30 69 M A             1 IM     
31 43 F A             1 IM     
32 33 M A             1 IM     
33 46 M A             1 IM     
34 77 M A             1 IM     
35 68 M A             1 IM     
36 48 M A             1 IM     
37 42 F A             1 IM     
38 57 M A   T315I         1 IM     
39 53 F A             1 IM     
40 51 M A             1 IM     
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Pt no 
Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 MUT 4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
 41 76 M A             1 IM     
42 42 M A             1 IM     
43 53 F A             1 IM     
44 47 M A             1 IM     
45 56 F A             1 IM     
46 68 F A             1 IM     
47 64 M A             1 IM     
48 33 F A             1 IM     
49 53 M A             1 IM     
50 79 M A             1 IM     
51 73 F A             1 IM     
52 51 M A             1 IM     
53 77 F A   H396R         1 IM     
54 69 F A             1 IM     
55 64 M A             1 IM     
56 91 M A             1 IM     
57 34 F A             1 IM     
58 54 M A             1 IM     
59 66 M A             1 IM     
60 71 M A             1 IM     
61 61 F A             1 IM     
62 46 M A             1 IM     
63 43 F A             1 IM     
64 55 M A             1 IM     
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65 32 F A             1 IM     
 
 
 
 
 
Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 MUT 4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
66 49 F A T           1 IM     
67 29 M A             1 IM     
68 75 M A             1 IM     
69 43 F A             1 IM     
70 55 F A             1 IM     
71 53 M A             1 IM     
72 60 M A             1 IM     
73 48 M A T N231S         1   IM   
74 82 M B             1 DASA IM   
75 42 F B             1 DASA IM   
76 61 M B T           1 DASA IM   
77 33 M B T           1 DASA   IM 
78 33 F B             1 IM DASA   
79 62 M B   F359I         1 IM; DASA     
80 62 M B             1 IM; DASA     
81 36 M B             1 IM; DASA     
82 21 M B             1 IM; DASA     
83 52 F B T           1 IM; DASA     
84 35 M B T           1 IM; DASA     
85 38 M B             1 IM; DASA     
86 71 M B             1 IM; DASA     
87 61 M B             1 IM; DASA     
88 61 M B             1 IM; DASA     
89 59 F B             1 IM; DASA     
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90 60 F B             1 IM; DASA     
91 38 F B             1 IM; DASA     
 
 
 
 
 
 
Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT IM1 MUT IM2 MUT 2 MUT 3 MUT 4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
92 66 M B             1 IM; DASA     
93 62 F B             1 IM; DASA     
94 66 F B             1 IM; DASA     
95 65 F B             1 IM; DASA     
96 52 M B             1 IM; DASA     
97 51 M B             1 IM; DASA     
98 40 M B             1 IM; DASA     
99 64 M B             1 IM; DASA     
100 41 M B   L384M             V338F       1 IM; DASA     
101 50 F B             1 IM; DASA     
102 57 F B             1 IM; DASA     
103 69 F B             1 IM; DASA     
104 54 F B             1 IM; DASA     
105 64 F B             1 IM; DASA     
106 73 M B             1 IM; DASA     
107 68 F B             1 IM; DASA     
108 88 F B   E276G         1 IM; DASA     
109 27 F B             1 IM; DASA     
110 69 F B             1 IM; DASA     
111 53 M B             1 IM; DASA     
112 45 F B   S417F         1 IM; DASA     
113 63 M B             1 IM; DASA     
114 48 F B             1 IM; DASA     
115 37 M B   E453V         1 IM; DASA     
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116 55 M B             1 IM; DASA     
117 32 M B             1   IM   
 
 
 
 
 
 
 
 
 
 
 
Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 MUT 4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
118 54 F C   F359V         1 IM     
119 33 M C   Q252H         1 IM; NILO     
120 38 M C             1 IM; NILO     
121 41 F C             1 IM; NILO     
122 52 F C             1 IM; NILO     
123 78 M C             1 IM; NILO     
124 38 F C             1 IM; NILO     
125 48 M C             1 IM; NILO     
126 25 F C             1 IM; NILO     
127 35 M C             1 IM; NILO     
128 24 M C             1 IM; NILO     
129 65 F C T           1 IM; NILO     
130 57 F C             1 IM; NILO     
131 45 F C             1 NILO IM   
132 64 F C             1 NILO IM   
133 45 F C   V299L         1 NILO IM   
134 55 F C T           1 NILO IM   
135 67 F C             1 NILO IM   
136 56 F C             1 NILO   IM 
137 66 M E             1 DASA; NILO IM   
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138 75 M E             1 IM; DASA; NILO     
139 60 M E             1 IM; DASA; NILO     
140 52 F E             1 IM; DASA; NILO     
141 70 M E             1 IM; DASA; NILO     
 140 
 
 
 
 
 
 
 
Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 
MUT 
4 
CCyR?  
Yes = 1   
No = 2 
CP AP BC 
142 69 M E    E450V (DASA)   1 IM; DASA; NILO   
143 65 F E  M351T H396R F317L (DASA)   1 IM; DASA; NILO   
144 67 M E T      1 NILO IM; DASA  
145 63 M E  L248V     1 NILO IM; DASA  
146 41 M E       1 NILO IM; DASA  
147 58 M E       1 NILO IM; DASA  
148 34 M F T      1 IM; NILO; DASA   
149 50 M F       1 IM; NILO; DASA   
150 73 F F    Y253H (NI LO)   1 IM; NILO; DASA   
151 57 F F       1 NILO; DASA IM  
152 42 F F       1 NILO; DASA IM  
153 35 M I       1 IM; DASA; BOSU   
154 79 M J    V299L (BOSU)   1 DASA; BOSU; NILO IM  
155 58 F K       1 BOSU IM; NILO  
156 35 M L T   T315I  (BOSU) 
 
F359V (BOSU) 
  1 BOSU IM  
157 62 M L      1 IM; BOSU   
158 65 F N       1 INF; IM   
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CCyR? 
Pt no.   Age Sex   
Treatment  T (green when MUT IM1 MUT IM2 MUT 2 MUT 3 MUT 4 Yes =1 CP AP BC 
Group s ucces ful) 
No = 2 
Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 MUT 4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
 
159 
 
54 
 
M 
 
O  
 
G250E     
 
1 
INF; IM; 
DASA 
  
160 62 M Q       1 HU; IM   
161 75 M R       1 IM; NILO HU  
162 63 M U       1 DASA   
163 66 M U       1 DASA   
164 65 F U       1 DASA   
165 65 M A  F359V     2 IM   
166 63 M A       2 IM   
167 49 M A       2 IM   
168 54 F A       2 IM   
169 61 M A       2 IM   
170 58 M A       2 IM   
171 61 F A       2 IM   
172 40 F A       2 IM   
173 61 F A       2 IM   
174 39 M A       2 IM   
175 52 M A       2 IM   
176 71 M A       2 IM   
177 69 M A  E255K     2 IM   
178 80 M A       2 IM   
179 64 M A       2 IM   
180 54 M A       2 IM   
181 76 M A       2 IM   
182 80 M A       2  IM  
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183 46 F A       2  IM  
 
 
CCyR? 
Pt no.   Age Sex   
Treatment  T (green when MUT IM1 MUT IM2 MUT 2 MUT 3 MUT 4 Yes =1 CP AP BC 
Group s ucces ful) 
No = 2 
Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 MUT 4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
184 64 M A T L364I     2  IM  
185 66 F A       2  IM  
186 70 F A       2  IM  
187 46 M A       2  IM  
188 63 M A       2  IM  
189 55 M A       2  IM  
190 18 M A  G250E     2  IM  
191 44 F A  H396R     2   IM 
192 47 M A T      2   IM 
193 80 F A       2   IM 
194 46 F A       2   IM 
195 90 F A  E355G     2   IM 
196 57 F A       2   IM 
197 88 F A  T315I G250E    2   IM 
 
198 
 
63 
 
F 
 
B 
  
F311I 
 T315I 
(DASA) 
   
2 
 
DASA 
 
IM 
 
 
199 
 
58 
 
M 
 
B 
 
T 
  E255K 
(DASA) 
   
2 
 
IM 
 
IM; DASA 
 
200 72 M B       2 IM  DASA 
 
201 
 
53 
 
M 
 
B 
  
G250E 
 T315I 
(DASA) 
   
2 
 
IM 
  
DASA 
202 76 M B       2 IM  DASA 
203 43 M B       2 IM  DASA 
204 82 F B       2 IM; DASA   
205 41 F B       2 IM; DASA   
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206 51 M B       2 IM; DASA   
207 75 F B       2 IM; DASA  
 
 
 
 
CCyR? 
Pt no.   Age Sex   
Treatment  T (green when MUT IM1 MUT IM2 MUT 2 MUT 3 MUT 4 Yes =1 CP AP BC 
Group s ucces ful) 
No = 2 
Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 MUT 4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
208 51 M B T E459K  V299L   2 IM; DASA   
 
209 
 
58 
 
F 
 
B 
   M244V 
(DASA) 
   
2 
  
IM 
 
DASA 
210 81 M B       2  IM; 
DASA 
 
211 53 M B T M244V     2  IM; 
DASA 
 
212 31 M B       2   IM; DASA 
 
213 
 
78 
 
M 
 
C 
   Y253H 
(NILO) 
   
2 
 
IM 
 
IM; NILO 
 
214 77 M C       2 IM NILO  
215 51 F C       2 IM NILO  
 
216 
 
49 
 
M 
 
C 
   T315I 
(NILO) 
   
2 
 
IM 
 
NILO 
 
217 37 F C       2 IM NILO  
218 74 F C       2 IM NILO  
219 50 M C  E255K     2 IM  NILO 
220 50 M C       2 IM; NILO   
 
221 
 
63 
 
F 
 
C 
   F359C 
(NILO) 
   
2 
 
IM; NILO 
  
222 52 F C       2 IM; NILO   
223 73 M C  E450K     2 IM; NILO   
224 64 M C       2 NILO IM  
 
225 
 
69 
 
F 
 
C 
   L387M 
(NILO) 
   
2 
 
NILO 
 
IM 
 
226 80 F C       2  IM; NIL  
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227 
 
45 
 
M 
 
C 
   E255V 
(NILO) 
   
2 
  
IM; NILO 
 
 
 
 
CCyR? 
Pt no.   Age Sex   
Treatment  T (green when MUT IM1 MUT IM2 MUT 2 MUT 3 MUT 4 Yes =1 CP AP BC 
Group s ucces ful) 
No = 2 
Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 
MUT 
4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
 
228 
 
44 
 
M 
 
C 
   T315I 
(NILO) 
   
2 
  
IM; NILO 
 
229 44 M C       2  IM; NILO  
230 59 M C       2   IM; NILO 
 
231 
 
67 
 
M 
 
D 
  
E459K 
 
T315I 
Y253H 
(NILO) 
   
2 
  
NILO; HHT 
 
IM 
 
232 
 
48 
 
M 
 
E 
 
T(2) 
 
G250E 
 T315A 
(DASA) 
   
2 
 
DASA; NILO 
  
IM 
 
233 
 
61 
 
M 
 
E 
 
T 
  F359V 
(NILO) 
   
2 
 
DASA; NILO 
  
IM 
 
234 
 
62 
 
M 
 
E 
 
T 
 
M351T 
 F317L 
(DASA) 
G250E 
(NILO) 
T315I 
(NILO) 
 
2 
 
IM 
 
DASA 
 
NILO 
 
235 
 
38 
 
M 
 
E 
 
T 
  T315I 
(NILO) 
   
2 
 
IM 
 
DASA; NILO 
 
 
236 
 
69 
 
F 
 
E 
       
2 
 
IM 
 DASA; 
NILO 
 
237 
 
60 
 
F 
 
E 
 
T 
  F317L 
(DASA) 
   
2 
 
IM 
 DASA; 
NILO 
 
238 
 
67 
 
M 
 
E 
  
M244V 
     
2 
IM, DASA; 
NILO 
  
 
239 
 
74 
 
F 
 
E 
   E255K 
(DASA) 
   
2 
IM; DASA; 
NILO 
  
 
240 
 
69 
 
F 
 
E 
       
2 
IM; DASA; 
NILO 
  
241 70 F E  F359V     2 IM; DASA NILO  
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242 
 
62 
 
F 
 
E 
 
T 
 
M244V 
 F317L 
(DASA) 
   
2 
 
IM; DASA 
 
NILO 
 
 
 
 
 
 
CCyR? 
Pt no.   Age Sex   
Treatment  T (green whe n MUT IM1 MUT IM2 MUT 2 MUT 3 MUT 4 Yes =1 CP AP BC 
Group s ucces ful)       
No = 2
 
243 69 F E  F486S  E462K (NI LO)   2 IM; DASA NILO  
244 41 F E       2 IM; DASA; NILO   
245 68 F E       2 IM; DASA; NILO   
246 67 F E       2 IM; DASA; NILO   
247 65 F E       2 IM; DASA; NILO   
248 76 M E       2 NILO IM; DASA  
249 67 F E       2  IM DASA; NI LO 
250 77 F E       2  IM; DASA NILO 
251 64 M E T      2  IM; DASA; NILO  
252 59 M F  F359V     2 DASA IM; NILO  
253 79 M F       2 IM I M; NI L; DASA  
254 64 F F  L384M     2 IM; NILO DASA  
255 54 F F T      2 IM; NILO; DASA   
256 65 M F  G250E     2 NIL; DASA IM  
257 71 M F  Y253H     2  DASA IM; NILO 
258 46 F G  T315I  G250E (DASA)   2  IM; DASA HHT 
259 41 M H T Y253F M351T E255K (NI LO)   2 NILO IM; HHT DASA 
 
 
 
 
 
 
 
 
 146 
 
 
 
 147 
 
 
 
 
 
 
 
Pt no Age Sex 
Treatment 
Group 
T (green 
when 
successful) 
MUT 
IM1 
MUT 
IM2 
MUT 2 MUT 3 MUT 4 
CCyR?  
Yes = 1   
No = 2  
CP AP  BC 
260 80 F L       2  IM; BOSU  
261 31 F M T      2 IM; INF   
262 81 M M  T315I     2 IM; INF   
263 65 M O  E453K     2 IM DASA INF 
 
264 
 
 
66 
 
 
M 
 
 
P 
 
 
 
G250E 
  
F317L 
(DASA) 
  
 
 
2 
INF; IM; 
HU; DAS; 
NIL 
  
 
265 
 
65 
 
F 
 
P 
 
T 
 
T315I 
 M244V 
(NILO) 
   
2 
INF; IM; 
HU; DASA 
 
NILO 
 
 
266 
 
74 
 
M 
 
S 
   G250E 
(NILO) 
   
2 
 
IM 
HU; INF; 
DASA; NILO 
 
 
267 
 
71 
 
M 
 
T 
   T315I 
(DASA) 
   
2 
 
IM; HU 
 
DASA 
 
268 70 M U       2  DASA  
269 73 M U       2  DASA  
 
 
 
 
 
 
 
 
 
 
